Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 12567. Отображено 100.
05-01-2012 дата публикации

Animal model for parkinson's disease

Номер: US20120005765A1
Автор: Michael Panneton, Vijaya Kumar, William Burke
Принадлежит: St Louis University

Disclosed are methods and compositions for an animal model of Parkinson's disease. In particular, disclosed is the use of antisense compounds to inhibit the expression of ALDH1A1 in the substantia nigra of an animal brain for the purpose of creating an animal that will displays the symptoms of a human with Parkinson's Disease, including various biochemical, histological, and behavioral characteristics. Also disclosed are methods for using the animal model for Parkinson's disease to test potential therapeutic agents for Parkinson's disease.

Подробнее
Номер записи: 1
09-02-2012 дата публикации

Artificial cells

Номер: US20120034155A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne R. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 2
09-02-2012 дата публикации

Artificial cells

Номер: US20120034157A1
Автор: Elizabeth A. Sweeney, Gary L. McKnight, Lowell L. Wood, JR., Muriel Y. Ishikawa, Roderick A. Hyde, Wayne A. Kindsvogel
Принадлежит: SEARETE LLC

The present disclosure relates to various embodiments associated with artificial cells, particularly artificial antigen presenting cells, methods of making the same, methods of administering the same, computer systems relating thereto, computer-implemented methods relating thereto, and associated computer program products.

Подробнее
Номер записи: 3
15-03-2012 дата публикации

Uniform Fluorescent Microspheres with Hydrophobic Surfaces

Номер: US20120064012A1
Автор: Yu-zhong Zhang
Принадлежит: Life Technologies Corp

Fluorescent microspheres for the measurement of blood flow are provided. The microspheres are substantially uniform in diameter and have a hydrophobic surface, which allows them to circulate more freely throughout bloodstream, while reducing immunogenicity, particle aggregation and bioaccumulation. The hydrophobic surface on each microsphere is generally comprised of polymeric material having a limited surface charge.

Подробнее
Номер записи: 4
15-03-2012 дата публикации

Fluorescent mri probe

Номер: US20120065384A1
Автор: Kenjiro Hanaoka, Takehiro Yamane, Tetsuo Nagano, Yasuaki Muramatsu
Принадлежит: University of Tokyo NUC

A fluorescent gadolinium complex compound comprising a residue of gadolinium.1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid or a residue of gadolinium.diethylenetriaminepentaacetic acid bound covalently with a group represented by the following general formula (I) (R 1 represents hydrogen atom or a substituent R 2 , R 4 , R 5 and R 7 represent hydrogen atom, a halogen atom or a C 1-6 alkyl group, and R 3 and R 6 represent hydrogen atom, a halogen atom or a C 1-6 alkyl group), which is easily taken up into cells and useful as a probe observable by the fluorescence method and MRI.

Подробнее
Номер записи: 5
19-04-2012 дата публикации

Molecularly Imprinted Polymers for Use as Imaging and Therapeutics Agents

Номер: US20120093720A1
Автор: Robert Jones, Thomas Beck
Принадлежит: Individual

The invention described herein provides biocompatible molecularly imprinted polymers (MIPs) that are non-toxic, water soluble, small molecular weight, and degradable in a living body. The MIPs are capable of binding to all or a portion of a specific target macromolecule associated with a disease located within the living body and they are derivatized for stealth for in vivo applications to avoid the reticuloendothelial system. The MIPs of the invention are functionalized to an amine or carboxyl group and are derivatized with an imaging and/or therapeutic agent for taking images of the disease and/or for providing therapy. The macromolecule can be selected from a group consisting of proteins, glycoproteins, lipoproteins, peptidoglycans, peptides, polypeptides, polynucleotides, and polysaccharides. The invention described herein also provides methods and kits wherein MIPs of the invention can be employed as targeted imaging and therapeutic agents.

Подробнее
Номер записи: 6
03-05-2012 дата публикации

Multivalent pcv2 immunogenic compositions and methods of producing such compositions

Номер: US20120107348A1
Автор: Greg Nitzel, Marc Eichmeyer, Michael Roof, Phillip Hayes
Принадлежит: Boehringer Ingelheim Vetmedica Inc

An improved method for recovering the protein expressed by open reading frame 2 from porcine circovirus type 2 is provided. Also provided is recombinant PCV2 ORF2 protein, and immunogenic compositions comprising PCV2 ORF2 protein. Moreover, multivalent combination vaccines are provided which include an immunological agent effective for reducing the incidence of or lessening the severity of PCV2 infection, preferably PCV2 ORF2 protein, or an immunogenic composition comprising PCV2 ORF2 protein, and at least one immunogenic active component of another disease-causing organism in swine,

Подробнее
Номер записи: 7
17-05-2012 дата публикации

Antibodies that immunospecifically bind to b lymphocyte stimulator protein

Номер: US20120121606A1
Автор: David Hilbert, Gil H. Choi, Steven C. Barash, Steven M. Ruben, Tristan Vaughan
Принадлежит: Human Genome Sciences Inc

The present invention relates to antibodies and related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention also relates to methods and compositions for detecting or diagnosing a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate function of B Lymphocyte Stimulator comprising antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator. The present invention further relates to methods and compositions for preventing, treating or ameliorating a disease or disorder associated with aberrant B Lymphocyte Stimulator expression or inappropriate B Lymphocyte Stimulator function comprising administering to an animal an effective amount of one or more antibodies or fragments or variants thereof or related molecules that immunospecifically bind to B Lymphocyte Stimulator.

Подробнее
Номер записи: 8
21-06-2012 дата публикации

Targeting agent to newly formed blood vessels

Номер: US20120156132A1
Автор: Kentaro Nakamura, Yasuhiko Tabata
Принадлежит: Fujifilm Corp, KYOTO UNIVERSITY

It is an object of the present invention to provide a targeting agent that enables drug delivery to a neovascular site and the imaging of such a neovascular site, utilizing the effect of the agent to accumulate in the neovascular site. The present invention provides a targeting agent to a neovascular site, which comprises a gelatin-like protein.

Подробнее
Номер записи: 9
05-07-2012 дата публикации

Arginase Inhibitors and Methods of Use Thereof

Номер: US20120171116A1
Автор: Bhaskara Rao Nallaganchu, Bruce Edward Tomczuk, Gary Lee Olson, Jane Wang, Richard Scott Pottorf
Принадлежит: Corridor Pharmaceuticals Inc

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

Подробнее
Номер записи: 10
02-08-2012 дата публикации

Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation

Номер: US20120196898A1
Автор: Rusiko Bourtchouladze, Thomas M. Hallam, Tim Tully
Принадлежит: Individual

The present invention provides methods of improving cognitive and motor deficits associated with central nervous system (CNS) disorder or condition in an animal. The methods comprise a general administration of phosphodiesterase 4 inhibitors and optionally training the animal under conditions sufficient to produce an improvement in performance.

Подробнее
Номер записи: 11
16-08-2012 дата публикации

Modified Variable Domain Molecules And Methods For Producing And Using Same

Номер: US20120207673A1
Автор: Daniel Christ, Kip Dudgeon
Принадлежит: GARVAN INSTITUTE OF MEDICAL RESEARCH

The present disclosure provides an isolated protein comprising an antibody heavy chain variable region (V H ) comprising a negatively charged amino acid at position 28 and/or 31 and/or 32 and/or 33 and/or 35 according to the numbering system of Kabat, the protein capable of binding specifically to an antigen.

Подробнее
Номер записи: 12
11-10-2012 дата публикации

Linkable Lewis X Analogs

Номер: US20120258043A1
Автор: Edmund R. Marinelli, Kondareddiar Ramalingam, Radhakrishna Pillai, Ramachandran Ranganathan, Rolf E. Swenson
Принадлежит: Bracco Suisse SA

Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe X ) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLe X compositions. In particular, the disclosed SLe X compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLe X compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl Le X , and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.

Подробнее
Номер записи: 13
25-10-2012 дата публикации

Intracellular Delivery of Contrast Agents with Functionalized Nanoparticles

Номер: US20120269730A1
Автор: Chad A. Mirkin, Thomas J. Meade, Xiaoyang Xu, Ying Song
Принадлежит: Northwestern University

The present invention is directed to compositions and methods for intracellular delivery of a contrast agent with a functionalized nanoparticle.

Подробнее
Номер записи: 14
25-10-2012 дата публикации

Micellar compositions for use in biological applications

Номер: US20120269736A1
Автор: Mark Green, Philip Howes
Принадлежит: KINGS COLLEGE LONDON

This invention relates to a composition comprising a micelle for use in biological applications, the micelle comprising: a substantially water-insoluble conjugated polymer which exhibits luminescence or fluorescence from about 300 nm to about 1500 nm of the electromagnetic spectrum: a biocompatible surfactant and/or lipid: and a MRI active agent.

Подробнее
Номер записи: 15
08-11-2012 дата публикации

Methods for measuring the metabolism of neurally derived biomolecules in vivo

Номер: US20120282642A1
Автор: David Michael Holtzman, Randall John Bateman
Принадлежит: Washington University in St Louis WUSTL

The present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for neurological and neurodegenerative diseases and disorders, such as Alzheimer's Disease, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. Methods of measuring the in vivo metabolism of biomolecules produced in the CNS in a subject are provided.

Подробнее
Номер записи: 16
22-11-2012 дата публикации

Antagonists of il-6 to raise albumin and/or lower crp

Номер: US20120294852A1
Автор: Jeffrey T.L. Smith
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Подробнее
Номер записи: 17
29-11-2012 дата публикации

Targeting and in vivo imaging of tumor-associated macrophages

Номер: US20120301394A1
Автор: Damya Laoui, Geert Raes, Jo Van Ginderachter, Kiavash Movahedi, Nick Devoogdt, Patrick De Baetselier, Steve Schoonooghe, Tony Lahoutte
Принадлежит: Vlaams Instituut voor Biotechnologie VIB

The invention relates to activities and characteristics of tumor-associated macrophages (TAMs). In particular, immunoglobulin single variable domains are provided against markers of TAMs, and methods using the same for in vivo imaging of tumor cells, as well as cancer diagnostics and therapeutics.

Подробнее
Номер записи: 18
03-01-2013 дата публикации

Adenosine derivative formulations for medical imaging

Номер: US20130004426A1
Автор: Ajit B. Thakur, Dianne D. Zdankiewicz, Hsun-Wen Hsu, James E. Anderson, James F. Castner
Принадлежит: Forest Laboratories Holdings Ltd

A stable composition useful for myocardial perfusion imaging contains one or more 2-alkynyladenosine derivatives; and a solvent which is made up of water and hydroxypropyl-β-cyclodextrin.

Подробнее
Номер записи: 19
24-01-2013 дата публикации

DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS

Номер: US20130022551A1
Автор: Nelson Ruiz-Opazo, Victoria L.M. Herrera
Принадлежит: Boston University

Provided herein are novel compositions comprising DEspR-specific antagonists and agonists, and methods of their use in a variety of therapeutic applications. The compositions comprising the DEspR-specific anatgonists and agonists described herein are useful in therapeutic, diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.

Подробнее
Номер записи: 20
31-01-2013 дата публикации

Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue and/or fever

Номер: US20130028860A1
Автор: Jeffrey T.L. Smith, John A. Latham, Mark Litton, Randall Schatzman
Принадлежит: Individual

The present invention is directed to therapeutic methods and compositions, especially subcutaneous and intravenous composition using antibodies and fragments thereof having binding specificity for IL-6 to prevent or treat cachexia, fever, weakness and/or fatigue in a patient in need thereof. In preferred embodiments, the anti-IL-6 antibodies will be humanized and/or will be aglycosylated. Also, in preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level. In another preferred embodiment, the patient's survivability or quality of life will preferably be improved.

Подробнее
Номер записи: 21
28-02-2013 дата публикации

Method and kit for quantifying risk predictor

Номер: US20130052139A1
Автор: Sven Lindskog
Принадлежит: DENTOSYSTEM SCANDINAVIA AB

A method and a kit for quantification of at least one predictor promoting at least one multifactorial disease, intended for use in assessment of the risk for developing or progression of the at least one multifactorial disease for a subject are disclosed. The kit comprises a plurality of reservoir units ( 320 ), each reservoir unit ( 320 ) being arranged to releasably retain a skin irritation agent adapted to provoke an unspecific inflammatory response of skin The kit comprises an estimation unit adapted to estimate a quantification of the at least one predictor on basis of an assessment of the at least one predictor performed by a user on basis of an assessment of the degree of severity of the inflammatory response to the skin irritation agent at each of a plurality of skin sites according to a predetermined inflammatory response criteria performed by the user and relative impact of the at least one predictor on the progress of the at least one multifactorial disease.

Подробнее
Номер записи: 22
14-03-2013 дата публикации

Infection activated wound caring compositions and devices

Номер: US20130064772A1
Автор: Gerald F. SWISS, Robert M. Moriarty, Stefan Schwabe
Принадлежит: Indicator Systems International Inc

Provided are wound caring compositions and devices containing a pH-sensitive, preferably acid degradable, components contained in a water-permeable and hydronium ion permeable material. The pH-sensitive component encloses an antibiotic which is released to the wound upon infection by a microorganism at the wound site, and/or encloses a pH indicator. The antibiotic release is triggered by the microorganism's production of CO 2 at the wound site which forms carbonic acid, lowers the pH at the pH sensitive components, and thus results in rupture of the liposome.

Подробнее
Номер записи: 23
11-04-2013 дата публикации

Artery- and vein-specific proteins and uses therefor

Номер: US20130091591A1
Автор: David J. Anderson, Hai U. Wang, Zhoufeng Chen
Принадлежит: California Institute of Technology CalTech

Arterial and venous endothelial cells are molecularly distinct from the earliest stages of angiogenesis. This distinction is revealed by expression on arterial cells of a transmembrane ligand, called EphrinB2 whose receptor EphB4 is expressed on venous cells. Targeted disruption of the EphrinB2 gene prevents the remodeling of veins from a capillary plexus into properly branched structures. Moreover, it also disrupts the remodeling of arteries, suggesting that reciprocal interactions between pre-specified arterial and venous endothelial cells are necessary for angiogenesis. This distinction can be used to advantage in methods to alter angiogenesis, methods to assess the effect of drugs on artery cells and vein cells, and methods to identify and isolate artery cells and vein cells, for example.

Подробнее
Номер записи: 24
18-04-2013 дата публикации

NUCLEIC ACID-MEDIATED SHAPE CONTROL OF NANOPARTICLES

Номер: US20130095039A1
Автор: Lu Yi, WANG Zidong
Принадлежит: The Board of Trustees of the University of Illinois

Embodiments of a method to use nucleic acid oligomer sequences for modulating the shape of nanoparticles are disclosed, as well as nanoparticles and methods of using the nanoparticles. Systematic variations of the nucleic acid sequences offer mechanistic insights into the morphology control. A plurality of nucleic acid oligomers is adsorbed onto a metal nanoseed to provide an oligomer-functionalized nanoparticle. Additional metal is deposited onto the oligomer-functionalized nanoparticle to produce a shaped nanoparticle having a morphology based at least in part on the nanoseed morphology and the oligomer's sequence composition. Embodiments of methods for using the shaped nanoparticles also are disclosed. 1. A method for making a shaped nanoparticle , comprising:providing a metal nanoseed;selecting a nucleic acid oligomer having an oligomer sequence composition comprising at least two unique sequence segments, each sequence segment having a length of at least five nucleobases selected from the group consisting of A, C, G, T, U, and modified nucleobases;adsorbing a plurality of the nucleic acid oligomers onto the metal nanoseed to produce an oligomer-functionalized nanoseed; anddepositing metal onto the oligomer-functionalized nanoseed to make a shaped nanoparticle, wherein the shaped nanoparticle has a morphology based at least in part on the oligomer sequence composition.2. The method of claim 1 , further comprising determining the morphology of the shaped nanoparticle claim 1 , wherein the morphology comprises shape claim 1 , surface characteristics claim 1 , or a combination thereof.3. The method of claim 2 , further comprising:providing a subsequent metal nanoseed having a morphology substantially similar to the metal nanoseed;selecting a subsequent nucleic acid oligomer having a subsequent oligomer sequence composition comprising at least two subsequent sequence segments, each subsequent sequence segment comprising nucleobases selected from the group consisting ...

Подробнее
Номер записи: 25
25-04-2013 дата публикации

METHOD AND APPARATUS FOR KIDNEY FUNCTION ANALYSIS

Номер: US20130101518A1
Автор: MOLITORIS Bruce A., SANDOVAL Ruben M., YU Weiming
Принадлежит: INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION

A method and apparatus for determining physiological data related to an animal, such as kidney diagnostics data, is provided. The method includes injecting a mixture of a first and a second molecule into an animal (e.g., a human patient), determining a molecular ratio of the molecules, and determining the physiological data based on the molecular ratio. The apparatus includes a number of finger receiving apertures, a light generation circuit, a light detection circuit, a pulse counting circuit, and a user interface. 145.-. (canceled)46. A method for determining the metabolic rate of a test molecule in an animal , the method comprising the steps of:a) administering a first molecule and a second molecule to the animal, wherein the second molecule is cleared from the animal at a rate lower than the rate at which the first molecule is cleared from the animal;{'sub': B', 'A', 'B', 'A', '(t)', 'B', 'A, 'claim-text': {'br': None, 'i': R', '/R', '=I', '/I, 'sub': B', 'A', 'B', 'A, ','}, 'b) determining the molecular ratio (R/R) of the first molecule to the second molecule in the animal over a period of time to obtain a time series of molecular ratios (R/R), the molecular ratio (R/R) being determined using the following equation{'sub': B', 'A, 'wherein Iis the level of the first molecule in the animal and Iis the level of the second molecule in the animal;'}{'sub': 1', 'B', 'A', '(t), 'claim-text': {'br': None, 'i': R', '/R', '=c+a', 'kt, 'sub': B', 'A', '(t), '()*exp(−),'}, 'c) determining the rate constant of organ clearance of the first molecule (k) from the time series of molecular ratios (R/R)using the equationwherein c is a constant, a is a pre-exponential factor, and t is time;{'sub': C/A', 'C/A', '(t), 'd) administering the test molecule for determination of the metabolic rate and the second molecule to the animal and determining the molecular ratio of the test molecule to the second molecule (R) over a period of time to obtain a time series of molecular ratios of ...

Подробнее
Номер записи: 26
25-04-2013 дата публикации

Modeling of pharmaceutical propagation

Номер: US20130102897A1
Автор: Arthur E. Uber, III, John F. Kalafut
Принадлежит: Medrad Inc

A method of delivering a contrast enhancing fluid to a patient using an injector system, including: determining at least one patient transfer function for the patient based upon data specific to the patient, the at least one patient transfer function providing a time enhancement output for a given input; determining a desired time enhancement output; using the at least one patient transfer function to determine an injection procedure input; and controlling the injector system at least in part on the basis of the determined injection procedure input.

Подробнее
Номер записи: 27
16-05-2013 дата публикации

METHODS FOR EVALUATING DERMAL FILLER COMPOSITIONS

Номер: US20130121920A1
Автор: Paliwal Sumit, Van Epps Dennis
Принадлежит: ALLERGAN, INC.

The present invention provides methods for evaluating dermal fillers for discoloration potential. 1. A method for evaluating a dermal filler composition , the method comprising:introducing into a skin region a dermal filler to be evaluated; andmeasuring discoloration in the skin region.2. The method of wherein the skin region is a skin region of a living animal.3. The method of wherein the skin region is a skin region of a living animal and the method further comprising reducing blood flow to the skin region prior to the step of measuring.4. The method of wherein the step of reducing blood flow comprises introducing a vasoconstrictor to the skin region.5. The method of wherein the step of reducing blood flow comprises euthanizing the animal.6. The method of wherein the euthanizing is performed at least 12 hours after the step of introducing.7. The method of wherein the euthanizing is performed at least 36 hours after the introducing.8. The method of wherein the euthanizing is performed at least 48 hours after the introducing.9. The method of wherein the observing is performed substantially immediately after the step of introducing into a skin region.10. The method of wherein the discoloration measured is a blue discoloration.11. The method of wherein the discoloration measured is discoloration resulting from Tyndall effect.12. The method of wherein the measuring comprises visually assessing the discoloration.13. The method of wherein the measuring comprises visually assessing the discoloration and assigning the discoloration a grade based on a numerical scale.14. The method of wherein the measuring comprises assessing the discoloration using an electromechanical device.15. The method of wherein the measuring comprises assessing the discoloration using reflectance spectroscopy.16. The method of wherein the measuring comprises quantifying a blue color component of the skin region.17. The method of wherein the measuring comprises quantifying a percentage (%) of blue ...

Подробнее
Номер записи: 28
16-05-2013 дата публикации

METHODS FOR EVALUATING AND SELECTING DERMAL FILLER COMPOSITIONS

Номер: US20130121922A1
Автор: Paliwal Sumit, Van Epps Dennis
Принадлежит: ALLERGAN, INC.

The present invention provides methods for selecting a cosmetically acceptable and effective dermal filler, with reduced chance of causing discoloration in skin of a patient. 1. A method for selecting a dermal filler composition comprising:quantifying a color component in a skin region of a patient; andselecting a dermal filler composition from a selection of different dermal filler compositions based on the quantified color component of the skin region of the patient.2. The method of wherein the step of quantifying comprisesintroducing into a skin region a dermal filler composition to be evaluated; andobserving discoloration in the skin region.3. The method of wherein the step of observing comprises measuring at least one color component of the skin region.4. The method of wherein the color component measured includes a blue color component.5. The method of wherein the step of quantifying further comprising reducing blood flow to the skin region prior to or during the step of observing.6. The method of wherein the step of reducing blood flow comprises introducing a vasoconstrictor to the skin region.7. The method of wherein the step of reducing blood flow comprises applying a vasoconstricting agent to the skin region.8. The method of wherein the vasoconstricting agent is applied topically to the skin region.9. The method of wherein the observing comprises comparing a color component observed in the skin region with the same color component observed in an untreated skin region.10. The method of wherein the observing comprises measuring a color component in the skin region and comparing the color component with the same color component of an untreated skin region of the same patient.11. The method of wherein the measuring comprises assessing the discoloration using an electromechanical device.12. The method of wherein the measuring comprises assessing the discoloration using reflectance spectroscopy.13. The method of wherein the measuring comprises quantifying a blue ...

Подробнее
Номер записи: 29
16-05-2013 дата публикации

Method for Diagnostically Imaging Lesions in the Peripheral Nervous System

Номер: US20130121928A1
Автор: Popinchalk Sam
Принадлежит:

An improved method for diagnosing and characterizing peripheral nerve lesions to permit early identification and characterization of peripheral nerve injuries that will require surgical intervention. 1. A method to diagnose and characterize peripheral nerve lesions , the method including the step of:introducing a chemical agent operable to bind directly to a peripheral nerve lesion in which the blood-nerve barrier is compromised,wherein the chemical agent does not interact with a target molecule unless the blood-nerve barrier is compromised.2. The method of claim 1 , further comprising the step of:attaching a label to the chemical agent,wherein the chemical agent with the label is operable to localize in regions where a peripheral of the blood-nerve barrier is disrupted.3. The method of claim 2 , further comprising the step of:quantitatively analyzing the peripheral nerve or nerves to determine the amount of labeling agent present.4. The method of claim 3 ,wherein the analyzing is performed using magnetic resonance imaging techniques.5. The method of claim 1 ,wherein the chemical agent is a monoclonal antibody.6. The method of claim 1 ,wherein the chemical agent is also operable to bind specifically and exclusively to the peripheral nerve lesions in which the blood-nerve barrier is compromised.7. The method of claim 1 ,wherein the peripheral nerve lesions in which the blood-nerve barrier is compromised is an antibody against an axonal protein.8. The method of claim 1 ,wherein the blood-nerve barrier is compromised as in neurotmesis.9. The method of claim 1 ,wherein the label attached to the chemical is gadolinium-DTPA or superparamagnetic iron oxide nanoparticles.10. The method of claim 1 ,wherein the method enables the accurate analysis of peripheral nerve lesions and the ability to distinguish axonotmetic lesions with greater self-regeneration potential from neurotmetic lesions that may require intervention. This patent application claims priority to U.S. Patent ...

Подробнее
Номер записи: 30
23-05-2013 дата публикации

Molecular Imaging of Cancer Cells In Vivo

Номер: US20130129619A1
Автор: Bui Marilyn M., Carter William Bradford, Enkemann Steven A., Gillies Robert J., Morse David L., Tafreshi Narges K.
Принадлежит: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods. 1. A non-invasive method for in vivo detection of cancer cells in a subject , the method comprising:administering to the subject a targeted imaging probe that specifically binds a cellular target selected from the group consisting of carbonic anhydrase 9 (CAIX), carbonic anhydrase 12 (CAXII), mammaglobin-A, carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), C-X-C motif chemokine 10 (CXCL10), and matrix metallopeptidase 9 (MMP-9); andimaging the subject with a molecular imaging device to detect the targeted imaging probe in the subject, wherein detection of the targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ.2. The method of claim 1 , wherein the cellular target is CAIX claim 1 , CAXII claim 1 , mammaglobin-A claim 1 , or a combination thereof.3. The method of claim 2 , comprising administering to the subject a first targeted imaging probe that specifically binds CAIX claim 2 , a second targeted imaging probe that specifically binds CAXII claim 2 , or a combination thereof claim 2 , wherein detection the first targeted imaging probe or the second targeted imaging probe in an organ of a subject is an indication of cancer cells in the organ.4. The method of claim 2 , comprising administering to the subject a targeted imaging probe that specifically binds mammaglobin-A claim 2 , wherein detection of the targeted imaging probe that specifically binds mammaglobin-A in an organ of a subject is an indication of breast cancer cells in the organ.5. The method of claim 1 , wherein the molecular imaging device comprises a gamma radiation detector.6. The method of claim 1 , wherein the targeted ...

Подробнее
Номер записи: 31
30-05-2013 дата публикации

DIAGNOSTIC REAGENTS

Номер: US20130136699A1
Автор: Vordermeier Hans, Whelan Adam
Принадлежит:

There is provided a skin test diagnostic reagent comprising at least one CFP-10 epitope polypeptide, at least one ESAT-6 epitope polypeptide and at least one Rv3615c epitope polypeptide, the reagent eliciting a positive result when administered in a skin test to an animal infected with or . The reagent is useful in that it can be used in a method to determine whether an animal is infected with or 1MycobacteriumMycobacterium tuberculosis.. A skin test diagnostic reagent comprising at least one CFP-10 epitope polypeptide , at least one ESAT-6 epitope polypeptide and at least one Rv3615c epitope polypeptide , characterised in that the reagent elicits a positive result when administered in a skin test to an animal infected with brevis or2. A diagnostic reagent according to which comprises one or more of the polypeptides having amino acid sequences SEQ ID NOs:35 claim 1 , 36 and 38.3. A diagnostic reagent according to which comprises one or more polypeptides having amino acid sequences SEQ ID NOs:1-10.4. A diagnostic reagent according to which comprises one or more polypeptides having amino acid sequences SEQ ID NOs: 11-21.5. A diagnostic reagent according to which comprises one or more polypeptides having amino acid sequences SEQ ID NOs:23-34.6. A diagnostic reagent according to which further comprises at least one MPB83 epitope polypeptide.7. A diagnostic reagent according to which comprises a polypeptide having amino acid sequence SEQ ID NO:37.8. A diagnostic reagent according to which comprises a polypeptide having amino acid sequence SEQ ID NO:22.9. A diagnostic reagent according to which comprises at least one polypeptide having amino acid sequence SEQ ID NO:33 or 34.10. A diagnostic reagent according to which comprises the polypeptides having amino acid sequences SEQ ID NOs:31 claim 1 , 32 and 34.11. A diagnostic reagent according to which comprises the polypeptides having amino acid sequence SEQ ID NOs:23-33.12. A diagnostic reagent according to which comprises ...

Подробнее
Номер записи: 32
06-06-2013 дата публикации

Combination of pimavanserin and risperidone for the treatment of psychosis

Номер: US20130143901A1
Автор: Daniel Van Kammen, Daun Bahr, David Furlano, Mark Brann, Perry Peters
Принадлежит: Acadia Pharmaceuticals Inc

Combinations of 5-HT2A inverse agonists or antagonists such as pimavanserin with antipsychotics such as risperidone are shown to induce a rapid onset of antipsychotic action and increase the number of responders when compared to therapy with the antipsychotic alone. These effects can be achieved at a low dose of the antipsychotic, thereby reducing the incidence of side effects. The combinations are also effective at decreases the incidence of weight gain and increased glucose or prolactin levels caused by the antipsychotic.

Подробнее
Номер записи: 33
20-06-2013 дата публикации

METHODS FOR THE TREATMENT AND THE DIAGNOSIS OF CANCER

Номер: US20130156702A1
Автор: Beck Laurent, Friedlander Gérard, Leroy Christine, Salaün Christine
Принадлежит: Institut National de la Sante et de la Recherche Medicale (INSERM)

The present invention relates to methods for the diagnostic and the staging of cancer such as liver cancer. The present invention also relates to methods for the treatment of cancer including liver cancer such as hepatocellular carcinoma (HCC). 1. A method for detecting or diagnosing a cancer and/or metastases in a patient comprising the step of determining an expression level of the phosphate transporter PiT1 gene in a biological sample obtained from said patient.2. A method for staging a cancer in a patient having cancer comprising the step of determining an expression level of the PiT1 gene in a biological sample obtained from said patient.3. A method for screening an asymptomatic patient at risk for cancer , said method comprising the step of determining an expression level of the PiT1 gene in a biological sample obtained from said patient.4. The method according to claim 1 , wherein said expression level of the PiT1 gene is determined by measuring a quantity of PiT1 mRNA claim 1 , and wherein and said biological sample is a tissue sample.5. The method according to claim 4 , wherein said tissue sample is a tumor sample.6. The method according to claim 1 , wherein said cancer is a liver cancer.7. The method according to claim 6 , wherein the liver cancer is a hepatocellular carcinoma (HCC).8. A method of detecting and localizing cancer cells and/or metastases stemming from cancer cells in the body of a patient claim 6 , comprising the steps ofadministering to said patient a labeled agent which binds to PiT1 in a quantity sufficient for imaging said patient,subjecting said body to imaging to produce images, andusing said images to detect and localize said cancer cells and/or said metastases.9. The method according to claim 8 , wherein the cancer cells are liver cancer cells.10. The method according to claim 9 , wherein said method is a method of detecting and localizing hepatic carcinoma nodules in situ in the body of a patient.11. A kit for detecting or ...

Подробнее
Номер записи: 34
20-06-2013 дата публикации

Methods, Compounds, and Compositions For Treatment and Prophylaxis in the Respiratory Tract

Номер: US20130156703A1
Автор: David Wurtman, Fang Fang, Michael Malakhov, Ron Moss
Принадлежит: Ansun Biopharma Inc, NexBio Inc

The present invention provides a method of reducing the quanitity of mucus in the respiratory tract of a subject with elevated levels of mucus in said respiratory tract. The method includes administering to the subject a compound or composition containing a therapeutically effective amount of a fusion protein comprising a sialidase or an active portion thereof and an anchoring domain. The therapeutically effective amount comprises an amount of the fusion protein that results in a reduction of the quanitity of mucus in the respiratory tract after administration of the compound or composition when compared to the quantity of mucus present prior to administration of the compound or composition.

Подробнее
Номер записи: 35
04-07-2013 дата публикации

In Vivo Copper-Free Click Chemistry for Delivery of Therapeutic and/or Diagnostic Agents

Номер: US20130171065A1
Автор: "DSouza Christopher A.", GOLDENBERG David M., McBride William J.
Принадлежит: IMMUNOMEDICS, INC.

The present application discloses compositions and methods of synthesis and use involving click chemistry reactions for in vivo or in vitro formation of therapeutic and/or diagnostic complexes. Preferably, the diagnostic complex is of use for F imaging, while the therapeutic complex is of use for targeted delivery of chemotherapeutic drugs or toxins. More preferably, a chelating moiety or targetable construct may be conjugated to a targeting molecule, such as an antibody or antibody fragment, using a click chemistry reaction involving cyclooctyne, nitrone or azide reactive moieties. In most preferred embodiments, the click chemistry reaction occurs in vivo. In vivo click chemistry is not limited to F labeling but can be used for delivering a variety of therapeutic and/or diagnostic agents. 1. A method of PET imaging comprising:{'sup': '18', 'a) attaching a metal-F complex to a chelating moiety;'}{'sup': '18', 'b) attaching the chelating moiety to a molecule by a click chemistry reaction in vitro to form an F-labeled molecule;'}c) administering the molecule to a subject; and{'sup': '18', 'd) imaging the distribution of the F-labeled molecule by PET (positron emission tomography).'}2. The method of claim 1 , wherein the click chemistry reaction is selected from the group consisting of: (i) a nitrone with a cycloalkyne; and (ii) an azide with a cycloalkyne.3. The method of claim 2 , wherein the cycloalkyne is cyclooctyne.4. The method of claim 1 , wherein the molecule is a protein or peptide.5. The method of claim 1 , wherein the molecule is a targeting molecule selected from the group consisting of an antibody claim 1 , a monoclonal antibody claim 1 , a bispecific antibody claim 1 , a multispecific antibody claim 1 , an antibody fusion protein claim 1 , an antigen-binding antibody fragment and an affibody.6. The method of claim 1 , wherein the molecule is a targetable construct.7. The method of claim 6 , further comprising:e) administering a targeting molecule to a ...

Подробнее
Номер записи: 36
04-07-2013 дата публикации

TREATMENT OF PITUITARY CORTICOTROPH TUMORS USING R-ROSCOVITINE

Номер: US20130171073A1
Автор: Liu Ning-Ai, Melmed Shlomo
Принадлежит: CEDARS-SINAI MEDICAL CENTER

The present invention describes methods of treating a pituitary tumor, methods of suppressing ACTH and/or corticosterone levels in an ACTH-secreting pituitary adenoma, methods of inhibiting the growth of an ACTH-secreting pituitary adenoma and methods of treating Cushing's disease. These methods can include providing a composition comprising R-roscovitin or a salt thereof and administering the composition to a mammalian subject in need thereof. 1. A method , comprising:providing a composition comprising a selective CDK/cyclin inhibitor; andadministering a therapeutically effective amount of the composition to a mammalian subject in need of treating a pituitary tumor, suppressing ACTH and/or corticosterone levels in a ACTH-secreting pituitary adenoma, inhibiting the growth of an ACTH-secreting pituitary adenoma, or treating Cushing's disease to treat the pituitary tumor, suppress the ACTH and/or corticosterone levels in a ACTH-secreting pituitary adenoma, inhibit the growth of an ACTH-secreting pituitary adenoma, or treat Cushing's disease.2. The method of claim 1 , wherein the mammalian subject is in need of treating a pituitary tumor and the pituitary tumor is treated.3. The method of claim 1 , wherein the pituitary tumor is a pituitary corticotroph tumor.4. The method of claim 3 , wherein the corticotroph tumor is a PTTG overexpressing corticotroph tumor.5. The method of claim 1 , wherein the mammalian subject is in need of suppressing ACTH and/or corticosterone levels in an ACTH-secreting pituitary adenoma and the ACTH and/or corticosterone levels in the ACTH-secreting pituitary adenoma are suppressed.6. The method of claim 1 , wherein the mammalian subject is in need of inhibiting the growth of an ACTH-secreting pituitary adenoma and the growth of an ACTH-secreting pituitary adenoma is inhibited.7. The method of claim 1 , wherein the mammalian subject is in need of treating Cushing's disease and Cushing's disease is treated.8. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 37
18-07-2013 дата публикации

METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA

Номер: US20130183248A1
Автор: Andrews Karen Mary, Harbeck Ronald J., JR. Donald, MacGlashan
Принадлежит:

Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria. 128-. (canceled)29. A method to monitor an individual's response to treatment of autoimmune chronic urticaria , wherein the individual has previously been diagnosed as having autoimmune chronic urticaria , the method comprising:a) contacting cells with a test biological sample from the individual before administering the treatment, wherein the cells are capable of expressing CD203c and FcεRIα, and upregulate the expression of CD203c upon stimulation of the FcεRIα, and wherein the cells are provided as present in a whole blood sample from a donor or as present in peripheral blood cells from a donor;b) contacting cells with a test biological sample from the individual after administering the treatment, wherein the cells are capable of expressing CD203c and FcεRIα, and upregulate the expression of CD203c upon stimulation of the FcεRIα, and wherein the cells are provided as present in a whole blood sample from a donor or as present in peripheral blood cells from a donor; andc) detecting expression of CD203c on the cells from steps (a) and (b), wherein statistically significant upregulation of CD203c on the cells in the presence of the test biological sample before administering the treatment, as compared to CD203c expression on the cells in the presence of the test biological sample after administering the treatment, indicates that the individual is responding to the treatment;wherein the upregulation of CD203c occurs due to stimulation of FcεRIα by ...

Подробнее
Номер записи: 38
25-07-2013 дата публикации

NANO-SCALE CONTRAST AGENTS AND METHODS OF USE

Номер: US20130189187A1
Автор: Annapragada Ananth, Bellamkonda Ravi V., Karathanasis Efstathios, Lebovitz Russell M.
Принадлежит:

Compositions and methods are disclosed for evaluating a subject's vasculature integrity, for differentiating between a malignant lesion and a benign lesion, for evaluating the accessibility of a tumor to nano-sized therapeutics, for treating tumors, and for live or real time monitoring of a nano-probe's biodistribution. 1. A method for evaluating a subject's vasculature integrity , the method comprising:introducing a composition into the subject's vasculature, the composition comprising: liposomes, a plurality of the liposome encapsulating one or more nonradioactive contrast-enhancing agents, and a plurality of the liposomes comprising: cholesterol, at least one phospholipid, and at least one phospholipid which is derivatized with a polymer chain, wherein the average diameter of the liposomes is less than 150 nanometers;generating images of the subject's vasculature; andanalyzing the images to detect a leak in the subject's vasculature.2. The method of claim 1 , wherein the generating images comprises generating X-ray images.3. The method of claim 1 , wherein the generating images comprises generating images before and after introducing the composition into the subject's vasculature.4. The method of claim 1 , wherein the analyzing the images comprises distinguishing areas having an enhanced signal from areas having little or no signal.5. The method of claim 1 , wherein the composition is characterized in that the composition accumulates in an extravascular region of the subject's vasculature when a leak exists in the subject's vasculature claim 1 , in comparison to an intravascular region of the subject's vasculature claim 1 , thereby enhancing the signal in the extravascular region.6. The method of claim 2 , wherein the generating X-ray images comprises generating X-ray images using at least one of computed tomography claim 2 , micro-computed tomography claim 2 , mammography claim 2 , and chest X-ray.7. The method of claim 1 , wherein the generating images ...

Подробнее
Номер записи: 39
25-07-2013 дата публикации

COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF DISEASES RELATED TO CELLS EXPRESSING IL-8 OR GRO-ALPHA, COMPRISING UCB-MSCs

Номер: US20130189189A1
Автор: CHANG Jong Wook, Kim Dal Soo, Oh Won II, YANG Yoon-Sun
Принадлежит: MEDIPOST CO., LTD.

Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs. 1. A method of preventing or treating a tumor comprising administering to a subject an effective dose of a composition comprising mesenchymal stem cells derived from umbilical cord blood (UCB-MSC).2. The method of claim 1 , wherein a cell of the tumor expresses at least one gene selected from a group of a gene encoding IL-8 and a gene encoding GRO-α.3. The method of claim 1 , wherein the tumor is selected from the group consisting of a brain tumor claim 1 , a liver hepatoma claim 1 , a breast cancer claim 1 , a colon cancer and a B-cell neoplasm.4. The method of claim 1 , wherein an anti-tumor agent gene is introduced into the UCB-MSC.5. The method of claim 4 , wherein the anti-tumor agent gene is selected from the group consisting of a tumor suppressor gene claim 4 , an apoptosis-inducing factor gene claim 4 , a cell cycle regulatory factor gene and an angiogenesis inhibitor gene.6. The method of claim 5 , wherein the tumor suppressor gene is selected from the group consisting of a gene encoding phosphatase and tensin homolog (PTEN) claim 5 , a gene encoding Maspin claim 5 , a gene encoding RUNX3 claim 5 , a gene encoding Caveolin-1 claim 5 , a gene encoding nm23 claim 5 , a gene encoding Rb protein claim 5 , a gene encoding Brush-1 claim 5 , a gene ...

Подробнее
Номер записи: 40
01-08-2013 дата публикации

MICELLULAR COMBINATION COMPRISING A NANOPARTICLE AND A PLURALITY OF SURFMER LIGANDS

Номер: US20130195755A1
Автор: Fuhrmann Christian, Kappen Sascha, Kloust Hauke, Moritz Hans-Ulrich, Pauer Werner, Poselt Elmar, Schmidtke Christian, Weller Horst
Принадлежит: CENTRUM FUR ANGEWANDTE NANOTECHNOLOGIE (CAN) GMBH

The field of the present invention relates to the stabilisation of nanoparticles in aqueous dispersion and, in particular, the stabilisation of nanoparticles by encapsulating the nanoparticles in a micellular combination. The field of the present invention further relates to a micellular combination of nanoparticles and a method of manufacture of the micellular combination and uses thereof. In a first aspect the present disclosure teaches a micellular combination that allows the stable dispersion of nanoparticles into aqueous environment. The micellular combination comprises at least one nanoparticle in a core of the micellular combination. A plurality of surfactants is co-assembled with a plurality of hydrophobic ligands on the surface of the nanoparticle in such a way that the hydrophilic part of the surfactant forms a hydrophilic shell around the core of the micellular combination. 1. A micellular combination comprising:at least one inorganic nanoparticle surrounded in a core of hydrophobic ligands,a plurality of ionic, zwitter-ionic or non-ionic surfactants comprising a hydrophilic moiety and a hydrophobic moiety, wherein the hydrophobic moiety surrounds the core of hydrophobic ligands with the at least one inorganic nanoparticle andat least one polymer chain of polymerisable monomers.2. The micellular combination according to claim 1 , comprising at least one copolymerised hydrophobic ligand and/or surfactant.3. The micellular combination of claim 1 , wherein the inorganic nanoparticle is any one of metal oxide claim 1 , metal nanoparticles claim 1 , rare earth doped nanoparticle or a semiconducting nanoparticle including quantum dots.4. The micellular combination according to claim 1 , comprising a mixture of different inorganic nanoparticles in the core.5. The micellular combination according to claim 1 , wherein the surfactant is an amphiphilic block copolymer.6. The micellular combination of claim 5 , comprising a surfmer or an amphiphilic di or multi-block ...

Подробнее
Номер записи: 41
01-08-2013 дата публикации

Methods and compositions for improving sleep and memory

Номер: US20130195763A1
Автор: Charles F. Landry, Jason R. Gerstner, Jerry C. Yin
Принадлежит: Individual

A method for determining whether a substance can increase the expression level of a fatty acid binding protein (FABP) in an animal. The method includes using a cell that includes an expression construct that comprises a FABP promoter operably linked to a polynucleotide sequence encoding a reporter molecule, wherein the cell is contacted with a candidate substance and then cultivating the cell under conditions conducive to expression of the reporter molecule. Increased expression of the construct in the presence of the candidate substance as compared to a control leads to improved sleep and long-term memory in the subject.

Подробнее
Номер записи: 42
08-08-2013 дата публикации

Multifunctional nanoplatforms for fluorescence imaging and photodynamic therapy developed by post-loading photosensitizer and fluorophore to polyacrylamide nanoparticles

Номер: US20130202525A1
Автор: Anurag Gupta, Munawwar Sajjad, Raoul Kopelman, Ravindra K. Pandey
Принадлежит: Health Research Inc, Research Foundation of State University of New York, University of Michigan

A composition comprising PAA nanoparticles containing a post loaded tetrapyrollic photosensitizer and a postloaded imaging agent and methods for making and using same.

Подробнее
Номер записи: 43
08-08-2013 дата публикации

PATHOLOGICAL ANIMAL MODEL SIMULTANEOUSLY DEVELOPING TESTICULAR PAIN OR DISCOMFORT BEHAVIORS AND URINARY FREQUENCY

Номер: US20130202534A1
Автор: Tanahashi Masayuki, Yoshioka Katsuro
Принадлежит: Astellas Pharma Inc.

A pathologic animal model characterized in that a pain or discomfort behavior and urinary frequency are induced by administering a stimulative substance into the testes of a small-sized mammal, and a screening method for a therapeutic agent for pelvic pain syndrome, particularly non-bacterial chronic prostatitis, which comprises administering a test substance to the pathologic animal model and measuring pain or discomfort behaviors and/or urinary frequency. 14.-. (canceled)5. A screening method for therapeutic agents for a pelvic pain syndrome , comprising:administering acetic acid or nerve growth factor (NGF) into the testes of a small-sized mammal; andadministering a test substance and measuring pain or discomfort behaviors and/or urinary frequency.6. The screening method for therapeutic agents described in claim 5 , wherein the pelvic pain syndrome is urological pain syndrome.7. The screening method for therapeutic agents described in claim 6 , wherein the urological pain syndrome is non-bacterial chronic prostatitis.8. The screening method described in claim 7 , which comprises administering the test substance before or after administration of a stimulative substance into the testes of the pathologic animal model claim 7 , and selecting the test substance that improves the pain or discomfort behavior and/or urinary frequency. This invention relates to a pathologic animal model which simultaneously develops testicular pain or discomfort behaviors and urinary frequency and a screening method for therapeutic agent for pelvic pain syndrome, particularly non-bacterial chronic prostatitis, by using the pathologic animal model.The pelvic pain syndrome is a general term for pain diseases at the pelvic area and defined by the International Continence Society in 2002 as “the occurrence of persistent or recurrent episodic pelvic pain associated with symptoms suggestive of lower urinary tract, sexual, bowel or gynecological dysfunction, without proven infection or other ...

Подробнее
Номер записи: 44
08-08-2013 дата публикации

Diagnostic reagents

Номер: US20130203087A1
Автор: Gareth Jones, Hans Vordermeier
Принадлежит: UK Secretary of State for Environment Food and Rural Affairs

There is provided a diagnostic reagent useful to determine whether an animal has a tuberculosis infection or has been exposed to a tuberculosis agent, for example a Mycobacterium . The reagent is useful to distinguish between such an animal and an animal which has been vaccinated against a tuberculosis infection.

Подробнее
Номер записи: 45
15-08-2013 дата публикации

PFKs as Modifiers of the IGFR Pathway and Methods of Use

Номер: US20130212716A1
Автор: Bjerke Lynn Margaret, Francis-Lang Helen, Friedman Lori S., Heuer Timothy S., Parks Annette L., Shaw Kenneth James
Принадлежит: Exelixis, Inc.

Human PFK genes are identified as modulators of the IGFR pathway, and thus are therapeutic targets for disorders associated with defective IGFR function. Methods for identifying modulators of IGFR, comprising screening for agents that modulate the activity of PFK are provided. 1. A method of identifying a candidate IGFR pathway modulating agent , said method comprising the steps of:(a) providing an assay system comprising a PFK polypeptide or nucleic acid;(b) contacting the assay system with a test agent under conditions whereby, but for the presence of the test agent, the system provides a reference activity; and(c) detecting a test agent-biased activity of the assay system, wherein a difference between the test agent-biased activity and the reference activity identifies the test agent as a candidate IGFR pathway modulating agent.2. The method of wherein the assay system comprises cultured cells that express the PFK polypeptide.3. The method of wherein the cultured cells additionally have defective IGFR function.4. The method of wherein the assay system includes a screening assay comprising a PFK polypeptide claim 1 , and the candidate test agent is a small molecule modulator.5. The method of wherein the assay is a kinase assay.6. The method of wherein the assay system is selected from the group consisting of an apoptosis assay system claim 1 , a cell proliferation assay system claim 1 , an angiogenesis assay system claim 1 , and a hypoxic induction assay system.7. The method of wherein the assay system includes a binding assay comprising a PFK polypeptide and the candidate test agent is an antibody.8. The method of wherein the assay system includes an expression assay comprising a PFK nucleic acid and the candidate test agent is a nucleic acid modulator.9. The method of wherein the nucleic acid modulator is an antisense oligomer.10. The method of wherein the nucleic acid modulator is a PMO.11. The method of additionally comprising:(d) administering the candidate ...

Подробнее
Номер записи: 46
22-08-2013 дата публикации

USE OF UTP FOR THE DIAGNOSIS OF STENOSES AND OTHER CONDITIONS OF RESTRICTED BLOOD FLOW

Номер: US20130216481A1
Автор: ROSENMEIER Jaya Brigitte
Принадлежит:

The present invention relates to methods for determining whether blood flow is restricted in a blood vessel of an individual suspected of compromised blood flow in the vessel, the method comprising the steps of delivering UTP, a derivative thereof, or a salt thereof to the vessel, assessing blood flow quantitatively in the vessel by obtaining a value that correlates to blood flow in said vessel, comparing the obtained value with a reference value, and determining whether the individual has compromised blood flow based on the results of the comparison. The invention also provides for methods of diagnosing atherosclerotic and ischemic heart diseases using UTP, a derivative thereof, or a salt thereof, as well as methods for inducing maximal hyperemia for diagnostic purposes. 117-. (canceled)18. A method for the induction of maximal hyperemia comprising delivering to an individual in need thereof an active diagnostic ingredient comprising UTP , or a pharmaceutically acceptable salt thereof , or a derivative thereof selected from the group consisting of UTPγS , MRS2498 , uridine-C , N5′-trisphosphate sodium salt solution , uridine-N5′-trisphosphate sodium salt solution , uridine-C , N5′-triphosphate sodium salt solution , uridine-N5′-triphosphate sodium salt solution , 2-diuridine tetraphosphate , thioUTP tetrasodium salt , denufosol tetrasodium , and UTPγS trisodium salt , β ,γ-imido-UTP , β ,γ-methylene-UTP , β ,γ-dichloromethylene-UTP , UPU , UPU , UPU , UPU , (N)-methanocarba-UTP , 2 ,2′-anhydro-UTP , 5-Br-UTP , 5-ethyl-UTP , 4-thio-UTP , 4-hexylthio-UTP , 5-(3-amino-1-propenyl)-2′-deoxyuridine-5′-triphosphate , tetrasodium 5-(3-amino-1-propenyl)-2′-deoxyuradine-5′-triphosphate , tetrapotassium 5-(3-amino-1-propenyl)-2′-deoxyuridine-5′-triphosphate , tetraammonium 5-(3-amino-1-propenyl)-2′-uridine-5′-triphosphate , tetrasodium 5-(3-amino-1-propenyl)-2′-uridine-5′-triphosphate , tetrapotassium 5-(3-amino-1-propenyl)-2′-uridine-5′-triphosphate , β ,γ-Difluoromethylene- ...

Подробнее
Номер записи: 47
29-08-2013 дата публикации

PERHEXILINE FOR TREATING CHRONIC HEART FAILURE

Номер: US20130224118A1
Автор: Frenneaux Michael Paul
Принадлежит: HEART METABOLICS LIMITED

Disclosed are methods for the treatment of chronic heart failure, comprising administering to an animal in need thereof an effective amount of perhexiline, or a pharmaceutically acceptable salt thereof, to treat said chronic heart failure. The chronic heart failure maybe non-ischaemic or ischaemic. Also disclosed is the use of perhexiline in the manufacture of a medicament to treat chronic heart failure, including chronic heart failure of a non-ischaemic origin and chronic heart failure of an ischaemic origin. 1. A method for treating chronic heart failure or a symptomatic component/feature/condition thereof in a mammal , comprising:diagnosing the mammal as having chronic heart failure or a symptomatic component/feature/condition thereof; andadministering to said mammal a therapeutically-effective amount of perhexiline.2. The method of claim 1 , wherein the therapeutically-effective amount of perhexiline is sufficient to reduce or ameliorate the chronic heart failure or a symptomatic component/feature/condition thereof in the mammal.3. The method of claim 1 , wherein the perhexiline is in the form of a pharmaceutically acceptable salt.4. The method of claim 2 , wherein the perhexiline is in the form of a maleate salt.5. The method of claim 1 , wherein the mammal is a human.6. The method of claim 1 , further comprising co-administering to said mammal at least one therapeutic compound.7. The method of claim 1 , further comprising co-administering to said mammal at least one therapeutic compound advantageous in treating chronic heart failure or a symptomatic component/feature/condition thereof.8. The method of claim 6 , wherein the therapeutic compound is selected from a member of the group consisting of Alpha Blockers claim 6 , Beta Blockers claim 6 , Calcium Channel Blockers claim 6 , Diuretics claim 6 , Ace (Angiotensin-Converting Enzyme) Inhibitors claim 6 , Arb (Angiotensin II Receptor Blockers) claim 6 , Spironolactone claim 6 , Nitrate claim 6 , Warfarin claim 6 ...

Подробнее
Номер записи: 48
05-09-2013 дата публикации

Diagnosis and treatment of brain tumors

Номер: US20130230453A1
Автор: Peter John Wookey, Sebastian Furness, Terrance Johns
Принадлежит: Welcome Receptor Antibodies Pty Ltd

The present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of cancer, as well as methods for treating or preventing cancer. In particular, the present invention relates to methods for the localisation, diagnosis, prognosis and/or prediction of therapeutic outcome of brain tumors expressing calcitonin receptor, as well as the treatment and prevention of brain tumors by targeting calcitonin receptor expressing brain tumour cells.

Подробнее
Номер записи: 49
05-09-2013 дата публикации

Papillomavirus pseudoviruses for detection and therapy of tumors

Номер: US20130230456A1
Автор: Douglas R. Lowy, Jeff Roberts, John T. Schiller
Принадлежит: National Institutes of Health NIH

Disclosed herein are methods of detecting tumors, monitoring cancer therapy, and selectively inhibiting the proliferation and/or killing of cancer cells utilizing a papilloma pseudovirus or a papilloma virus-like particle (VLP)

Подробнее
Номер записи: 50
05-09-2013 дата публикации

Tumor-Targeting Monoclonal Antibodies to FZD10 and Uses Thereof

Номер: US20130230521A1
Автор: Keigo Endo, Shuichi Nakatsuru, Toyomasa Katagiri, Yusuke Nakamura
Принадлежит: Individual

The present invention relates to an antibody or a fragment thereof which is capable of binding to a Frizzled homologue 10 (FZD10) protein, such as a mouse monoclonal antibody, a chimeric antibody and a humanized antibody. Also, the present invention relates to a method for treating and/or preventing FZD10-associated disease; a method for diagnosis or prognosis of FZD10-associated disease; and a method for in vivo imaging of FZD10 in a subject.

Подробнее
Номер записи: 51
12-09-2013 дата публикации

Phosphodiesterase activity and regulation of phosphodiesterase 1b-mediated signaling in brain

Номер: US20130239234A1
Автор: David Repaske, Gretchen Snyder, Paul Greengard
Принадлежит: Individual

The present invention provides methods and compositions for modulating the activity of phosphodiesterase 1B (PDE1B) in intracellular signaling pathways, including but not limited to, dopamine D1 intracellular signaling pathways. The invention also provides methods and compositions for modulating the activities of intracellular signaling molecules, including, but not limited to, DARPP-32 and GluR1 AMPA receptor, via modulation of PDE1B. The invention also provides pharmaceutical compositions and methods of screening for compounds that modulate PDE1B activity. The invention also provides methods of treating or ameliorating the symptoms of a disorder, including but not limited to a PDE1B-related disorder or a dopamine D1 receptor intracellular signaling pathway disorder, by administering a modulator of PDE1B, preferably, but not limited to, an inhibitor of PDE1B or an agent that decreases the production of PDE1B.

Подробнее
Номер записи: 52
12-09-2013 дата публикации

METHODS FOR TESTING FOR CALORIC RESTRICTION (CR) MIMETICS

Номер: US20130239235A1
Автор: Zhao-Wilson Xi
Принадлежит: BioMarker Pharmaceuticals, Inc.

Methods for treating neurological diseases and for testing Caloric Restriction (CR) mimetics or CR mimetic candidates. In one exemplary method, a CR mimetic candidate is administered to a transgenic animal and the effects of the administering are determined; the transgenic animal includes an added gene from another type of animal or a modified gene which is designed to produce a disease or ailment of another type of animal, and the method seeks to determine whether the CR mimetic candidate improves the disease or ailment. Methods relating to neurological disease and other methods relating to CR mimetic testing are also described. 1. A method of determining effects of administering a Caloric Restriction (CR) mimetic or a CR mimetic candidate to a subject , the method comprising:administering at least one of the CR mimetic or the CR mimetic candidate to the subject, the subject having a disease or ailment;determining the effects of the administering wherein the determining comprises determining whether the administering improves the disease or ailment; andperforming a plurality of other tests using the at least one of the CR mimetic or the CR mimetic candidate, wherein at least one of the plurality of other tests comprises determining a protective effect of the CR mimetic or the CR mimetic candidate against oxidative damage to mitochondria by (1) inducing oxidative damage to the mitochondria, (2) administering an amount of the CR mimetic or the CR mimetic candidate sufficient to inhibit the induced oxidative damage in the mitochondria, and (3) evaluating the effect of the CR mimetic or the CR mimetic candidate on mitochondrial complex activity.2. The method of wherein only the CR mimetic candidate is administered in the administering and wherein determining comprises determining whether the effects of the administering indicate that the CR mimetic candidate is a CR mimetic.3. The method of wherein the subject is a transgenic fly and the transgene is an added gene from ...

Подробнее
Номер записи: 53
19-09-2013 дата публикации

AGENTS FOR THE MOLECULAR IMAGING OF SERINE-PROTEASE IN HUMAN PATHOLOGIES

Номер: US20130243691A1
Автор: Fournie-Zaluski Marie-Claude, Leguludec Dominique, MICHEL Jean-Baptiste, Poras Herve, Roques Bernard, Rouzet Francois
Принадлежит: PHARMALEADS

The present invention is directed to the use of an irreversible ligand of a serine protease selected from the group consisting of leukocyte elastase, thrombin, tissue plasminogen activator (t-PA) and plasmin for the molecular imaging of said serine protease and the diagnosis of pathophysiological conditions associated with said serine protease activity. 1. A serine protease-targeted molecular imaging agent comprising at least one irreversible peptide ligand of a serine protease associated with at least one detectable moiety , wherein said serine protease is selected from the group consisting of leukocyte elastase , thrombin , tissue plasminogen activator (t-PA) and plasmin.5. The serine protease-targeted molecular imaging agent according to wherein said serine protease is plasmin claim 1 , and wherein said at least one irreversible peptide ligand is D-Val-Phe-Lys-cmk claim 1 , where -cmk is aminoacyl chloromethylketone.6. The serine protease-targeted molecular imaging agent according to claim 1 , wherein the at least one detectable moiety is an entity that is detectable by molecular imaging techniques.7. The serine protease-targeted molecular imaging agent according to claim 15 , wherein the at least one detectable moiety is a radionuclide detectable by PET.8. The serine protease-targeted molecular imaging agent according to claim 15 , wherein the at least one detectable moiety is a radionuclide detectable by planar scintigraphy or SPECT.9. The serine protease-targeted molecular imaging agent according to claim 15 , wherein the at least one detectable moiety is detectable by Magnetic Resonance Imaging (MRI).10. (canceled)11. A pharmaceutical composition comprising at least one serine protease-targeted molecular imaging agent according to and at least one pharmaceutically acceptable carrier.12. The serine protease-targeted molecular imaging agent of claim 2 , wherein said protective group is Acetyl (Ac) or tButyloxycarbonyl (Boc).13. The serine protease-targeted ...

Подробнее
Номер записи: 54
19-09-2013 дата публикации

Novel Chimeric Proteins and Methods for Using The Same

Номер: US20130243697A1
Автор: Jui-Han Huang, Mark L. Tykocinski
Принадлежит: University of Pennsylvania Penn

Novel chimeric proteins are disclosed. The proteins comprise at least two portions. The first portion binds to a first cell and decreases the cell's ability to send a trans signal to a second cell; the second portion sends its own trans signal to the second cell. Methods for making and using these proteins in the treatment of cancer, viral infections, autoimmune and alloimmune diseases are also disclosed, as are pharmaceutical formulations comprising the novel chimeric proteins and genes. Either the proteins themselves or a genetic sequence encoding the protein can be administered. Other methods are also disclosed in which two molecular components result in decrement of a first trans signal from a first cell and the conferring of a second trans signal to a second cell.

Подробнее
Номер записи: 55
19-09-2013 дата публикации

Proteomic Antisense Molecular Shield and Targeting

Номер: US20130243700A1
Автор: David Geho, Emanuel Petricoin, Lance Liotta
Принадлежит: Individual

The present invention provides compositions and methods for shielding and directing agents to biological targets in cellular systems for therapeutic, prophylactic, and diagnostic uses. Vascular devices are also provided which have coated surfaces that contain proteomic antisense, as well as therapeutic and other biological agents attached thereto.

Подробнее
Номер записи: 56
19-09-2013 дата публикации

IDENTIFICATION OF TISSUE FOR DEBRIDEMENT

Номер: US20130245386A1
Автор: Fruchterman Todd Matthew, Kieswetter Kristine, McNulty Amy K.
Принадлежит:

Provided are methods of determining whether a cell in a tissue site is viable or nonviable. Also provided are methods of debriding tissue from a tissue site. Further provided are kits comprising a compound that distinguishes between viable and nonviable cells and instructions for using the compound on a tissue site. Additionally, the use of a compound that distinguishes between viable and nonviable cells is provided, where the use is to determine whether a cell in a tissue site is viable or nonviable. Also provided is a use of a compound that distinguishes between viable and nonviable cells, where the use is for the manufacture of the above-described kit. 120-. (canceled)21. A method of determining the viability of a cell in a tissue site , the method comprising:adding a compound to the tissue site that identifies a molecule having an elevated or depleted level during cell death as compared to the molecule level in healthy tissue;allowing the compound to react with the molecule; anddetermining whether the molecule has an elevated or depleted level as an indication that the cell is nonviable.22. The method of claim 21 , further comprising:placing a solid sheet comprising the compound on the tissue site, wherein the compound is capable of binding or reacting to the released molecule on the tissue site; anddetermining whether the molecule is bound or has reacted to the compound, wherein areas of the sheet comprising molecule bound to the compound are indicative of nonviable tissue.23. The method of claim 22 , wherein the sheet is a starch film claim 22 , a poly(D claim 22 ,L-lactide-co-glycolide) claim 22 , a polyglycolic acid claim 22 , a poly-(L-lactic acid) claim 22 , or a polyhydroxyalkanoate.24. The method of claim 21 , wherein the compound identifies a molecule that is depleted during cell death.25. The method of claim 21 , wherein the compound comprises a dye capable of reacting with said molecule.26. The method of claim 21 , wherein the molecule is a metabolite ...

Подробнее
Номер записи: 57
26-09-2013 дата публикации

LIGANDS TO RADIATION-INDUCED MOLECULES

Номер: US20130251628A1
Автор: Hallahan Dennis E., Han Zhaozhong, Qu Shimian
Принадлежит: VANDERBILT UNIVERSITY

A method for identifying a molecule that binds an irradiated tumor in a subject and molecules identified thereby. In some embodiments, the method includes the steps of (a) exposing a tumor to ionizing radiation; (b) administering to a subject a library of diverse molecules; and (c) isolating from the tumor one or more molecules of the library of diverse molecules, whereby a molecule that binds an irradiated tumor is identified. Also provided are targeting ligands that bind an irradiated tumor and therapeutic and diagnostic methods that employ the disclosed targeting ligands. 1. A composition for guided targeting , wherein the composition comprises one or more targeting ligands comprising an amino acid sequence as set forth in SEQ ID NO: 40.2. The composition of claim 1 , wherein the one or more targeting ligands bind to one or more of an irradiated glioma claim 1 , a melanoma claim 1 , and a lung carcinoma.3. The composition of claim 1 , wherein the one or more targeting ligands bind to an irradiated tumor of two or more tumor types.4. The composition of claim 3 , wherein the one or more targeting ligands bind to an irradiated tumor of three or more tumor types.5. The composition of claim 4 , wherein the one or more targeting ligands bind to an irradiated glioma claim 4 , a melanoma claim 4 , and a lung carcinoma.6. The composition of claim 1 , wherein the composition further comprises a detectable label claim 1 , a therapeutic agent claim 1 , a drug carrier claim 1 , or combinations thereof.7. The composition of claim 6 , wherein the detectable label is an in vivo detectable label that can be detected using magnetic resonance imaging claim 6 , scintigraphic imaging claim 6 , ultrasound claim 6 , or fluorescence.8. The composition of claim 7 , wherein the in vivo detectable label comprises a radionuclide label selected from the group consisting of I or Tc.9. The composition of claim 6 , wherein the therapeutic agent is selected from the group consisting of a ...

Подробнее
Номер записи: 58
26-09-2013 дата публикации

Methods and compositions for protection of cells and tissues from computed tomography radiation

Номер: US20130251634A1
Автор: David J. Grdina
Принадлежит: University of Chicago

Described are methods for preventing or inhibiting genomic instability and in cells affected by diagnostic radiology procedures employing ionizing radiation. Embodiments include methods of preventing or inhibiting genomic instability and in cells affected by computed tomography (CT) radiation. Subjects receiving ionizing radiation may be those persons suspected of having cancer, or cancer patients having received or currently receiving cancer therapy, and or those patients having received previous ionizing radiation, including those who are approaching or have exceeded the recommended total radiation dose for a person.

Подробнее
Номер записи: 59
26-09-2013 дата публикации

HUMANIZED TRANSGENIC ANIMAL

Номер: US20130254907A1
Автор: Zhu James
Принадлежит:

This present invention relates to transgenic animals useful to study human diseases. Specifically, the invention relates to transgenic animals expressing at least two human proteins (optionally in replacement of the counterpart proteins in the animal) whereas a first human protein interacts with a second human protein. The transgenic animals can then be used for evaluating drugs or building disease models that are related to the expressed human proteins in the animals. The animals and methods disclosed herein reduce the possibility identifying a false-positive compound—the compound that show an effect in a naturally-occurring, non-transgenic animal but may not necessarily work or be therapeutic in human, since the compound may only interrupt the interaction between two animal proteins not necessarily two related human proteins. Also, the animals and methods disclosed herein reduce the possibility of identifying a false-negative compound—a compound that does not work or have any effect in a naturally-occurring, non-transgenic animal but may have therapeutic effect in human, since the compound may only interrupt the interaction between at least two relevant human proteins not necessarily two related animal proteins. 1. A humanized transgenic animal comprising a first human gene encoding a first human protein and a second human gene encoding a second human protein , wherein the first human protein and the second human protein interacts with each other.2. The humanized transgenic animal of wherein a first animal gene substantially homologous to the first human gene in the transgenic animal genome is replaced by the first human gene.3. The humanized transgenic animal of wherein a first animal gene substantially homologous to the first human gene in the transgenic animal genome is replaced by the first human gene and a second animal gene substantially homologous to the second human gene in the transgenic animal genome is replaced by the second human gene.4. The humanized ...

Подробнее
Номер записи: 60
26-09-2013 дата публикации

CLONED TRANSMEMBRANE RECEPTOR FOR 24-HYDROXYLATED VITAMIN D COMPOUNDS AND USES THEREOF

Номер: US20130254910A1
Автор: St-Arnaud Rene
Принадлежит: Shriners Hospital for Children

The instant invention relates to the use of 24-hydroxylated vitamin D compounds as therapeutics in mammalian bone fracture repair. In addition, the instant invention relates to novel 24-hydroxylated vitamin D compound receptors which can be employed in the development of compounds capable of facilitating fracture repair in animals. The instant invention also relates to nucleic acids encoding such receptors as well as vectors, host cells, transgenic animals comprising such nucleic acids and screening assays employing such receptors. 1. A transgenic non-human mammal comprising a disruption in an endogenous 24-hydroxylated vitamin D compound receptor gene.2. The transgenic non-human mammal of claim 1 , wherein said transgenic non-human mammal is selected from the group consisting of a pig claim 1 , a sheep claim 1 , and a rodent.3. The transgenic non-human mammal of claim 2 , wherein the transgenic non-human mammal is a rodent selected from the group consisting of a mouse and a rat.4. The transgenic non-human mammal of claim 3 , wherein the transgenic non-human mammal is a mouse.5. The transgenic non-human mammal of claim 1 , wherein the disruption is selected from the group consisting of: an insertion mutation claim 1 , a deletion mutation claim 1 , and a substitution mutation.6. The transgenic non-human mammal of claim 5 , wherein the disruption creates a cell-type specific inactivation of the 24-hydroxylated vitamin D compound receptor gene.7. The transgenic non-human mammal of claim 1 , further comprising a transgene encoding a heterologous 24-hydroxylated vitamin D compound receptor gene.8. The transgenic non-human mammal of claim 7 , wherein the transgenic non-human mammal is a mouse and the heterologous 24-hydroxylated vitamin D compound receptor gene is a human 24-hydroxylated vitamin D compound receptor gene.9. The transgenic non-human mammal of where in the transgenic non-human mammal is heterozygous for the disruption in the endogenous 24-hydroxylated ...

Подробнее
Номер записи: 61
03-10-2013 дата публикации

CELL CULTURE SCREEN FOR AGENTS THAT CONTROL ADIPOGENESIS AND MYOFIBROBLAST DIFFERENTIATION

Номер: US20130259807A1
Автор: Bahrami Seyed Bahram, Bissell Mina J., Turley Eva A.
Принадлежит: The Regents of the University of California

Methods are provided for the rapid and robust screening test agents for adipogenic activity. Agents testing positive in the assays are good candidate agents for wrinkle reduction, normalizing skin appearance after reconstructive or cosmetic surgery, e.g., grafted tissue on burn victims, normalizing skin appearance during and after wound healing, and the like. In certain embodiments the methods involve providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from differentiation into adipocytes; contacting the cells with the test agent(s); and screening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic. 1. A method of screening a test agent for adipogenic activity , said method comprising:providing mammalian test cells with adipogenic potential wherein said cells are primed for, but withheld from, differentiation into adipocytes;contacting said cells with said test agent; andscreening said test cells for an adipocyte phenotype wherein the presence of a feature characteristic of an adipocyte is an indicator that said test agent is adipogenic.2. The method of claim 1 , wherein said cells with adipogenic potential are cells selected from the group consisting of mesenchymal stem cells claim 1 , papillary and reticular dermal fibroblasts claim 1 , adipose derived stem/stromal cells claim 1 , preadipocytes claim 1 , myeloid precursors claim 1 , myogenic precursors with adipogenic potential claim 1 , vascular cells claim 1 , embryonic ectoderm claim 1 , and embryonic mesoderm.3. The method of claim 2 , wherein said cells with adipogenic potential are preadipocytes derived from skin claim 2 , preadipocytes derived from liposuction claim 2 , hair follicles claim 2 , and preadipocytes derived from liposarcoma.4. The method of claim 2 , wherein said cells with adipogenic potential are selected from the group consisting of ...

Подробнее
Номер записи: 62
03-10-2013 дата публикации

CANCER IMAGING WITH THERAPY: THERANOSTICS

Номер: US20130263296A1
Автор: Bhang Hyo-eun, Fisher Paul, Pomper Martin Gilbert
Принадлежит:

Genetic constructs comprising reporter genes operably linked to cancer specific or cancer selective promoters (such as the progression elevated gene-3 (PEG-3) promoter) are provided, as are methods for their use in cancer imaging, cancer treatment, and combined imaging and treatment protocols. Transgenic animals in which a reporter gene is linked to a cancer specific or cancer selective promoter, and which may be further genetically engineered, bred or selected to have a predisposition to develop cancer, are also provided. 1. A method of imaging tumors or cancerous cells or tissue in a subject , comprising the steps ofadministering to said subject a nucleic acid construct comprisingan imaging reporter gene operably linked to a cancer specific or cancer selective promoter;administering to said subject an imaging agent that is complementary to said imaging reporter gene; andimaging tumors or cancerous tissues or cells in said subject by detecting a detectable signal from said imaging agent.2. The method of claim 1 , wherein said imaging reporter gene is selected from the group consisting of luciferase and herpes simplex virus I thymidine kinase (HSV1-tk).3. The method of claim 1 , wherein said imaging reporter gene is HSV1-tk and said subject is a cancer patient.4. The method of claim 1 , wherein said imaging agent is a radiolabeled nucleoside analog.5. The method of claim 4 , wherein said radiolabeled nucleoside analog is 2′-fluoro-2′deoxy-β-D-5-[I]iodouracil-arabinofuranoside claim 4 ,6. The method of claim 1 , wherein said step of imaging is carried out via single photon emission computed tomography (SPECT) or by positron emission tomography (PET)7. The method of claim 1 , wherein said imaging reporter gene is luciferase and said subject is a laboratory animal.8. The method of claim 7 , wherein said imaging agent is a luciferase substrate.9. The method of claim 1 , wherein said nucleic acid construct is present in a polyplex with a cationic polymer.10. The method ...

Подробнее
Номер записи: 63
10-10-2013 дата публикации

HB-EGF DEFICIENT TRANSGENIC ANIMAL AND PRODUCTION METHOD THEREOF

Номер: US20130269045A1
Автор: Ueda Hiroshi
Принадлежит:

A transgenic animal other than human in which neuropsychiatric disorder condition is developed by the deletion of an HB-EGF gene is obtained. The present invention relates to a transgenic animal other than human in which an HB-EGF gene is deficient and neuropsychiatric disorder condition is developed, and a production method thereof, and a method for screening a therapeutic agent for neuropsychiatric disorder. As a transgenic animal in accordance with the present invention, a transgenic animal in which an HB-EGF gene is specifically deficient in the spiny neurons (striatum, and hippocampus) can be obtained by crossbreeding a transgenic animal that contains a genotype of Gng7, and a transgenic animal that contains a genotype of Hb-egf. 1. A transgenic animal other than human ,wherein an HB-EGF gene is deficient in hippocampal neuron region thereof, thereby the deficient causes neuropsychiatric disorder.2. The transgenic animal other than human in accordance with claim 1 ,wherein the transgenic aminal is obtained by crossbreeding a first transgenic animal other than human that contains a gene promoter being specifically expressed in a hippocampal neuron region and a Cre gene sequence, and a second transgenic animal other than human that contains an HB-EGF gene sequence sandwiched in between LoxP sequences.3. The transgenic animal other than human in accordance with claim 2 ,wherein the gene promoter is a Gng7 promoter, a CamK II promoter, or a Emx1 promoter.4. The transgenic animal other than human in accordance with claim 1 ,wherein the neuropsychiatric disorder is any one of depression, Alzheimer disease, psychiatric disorder, learning disability, and long-term memory impairment.5. The transgenic animal other than human in accordance with claim 1 ,wherein the transgenic animal other than human is a mouse.6. A method for screening a therapeutic agent for neuropsychiatric disorder claim 1 ,{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administrating a test ...

Подробнее
Номер записи: 64
17-10-2013 дата публикации

Compounds and methods of modulating mitochondrial bioenergetic efficiency through an interaction with atp synthase (complex v) and its subunits

Номер: US20130273557A1
Автор: Elizabeth Ann Jonas, Kambiz Nassirpour Alavian, Steven Dworetzky, Valentin Gribkoff
Принадлежит: Elizabeth Ann Jonas, Kambiz Nassirpour Alavian, Steven Dworetzky, Valentin Gribkoff

The present invention provides, in part, methods of identifying compounds that can bind to an ATP synthase complex, increase bioenergetic efficiency, decrease oxygen consumption or the rate thereof, increase oxygen utilization efficiency, increase cell survival or any combination thereof, and methods of using compounds and/or identified compounds to increase bioenergetic efficiency, increase oxygen utilization efficiency, decrease oxygen consumption, increase cell survival, or any combination thereof.

Подробнее
Номер записи: 65
24-10-2013 дата публикации

DESALINATION OF A COMPOSITION COMPRISING A CONTRAST AGENT

Номер: US20130277221A1
Автор: Birkeland Aslaug
Принадлежит: GE HEALTHCARE AS

The invention relates to industrial preparation of contrast agents, and further to an improved process for the purification of contrast agents. In particular, it relates to a process for reducing the salt content of compositions comprising an MR contrast agent or an X-ray contrast agent, such as a non-ionic iodinated monomeric compound or a non-ionic iodinated dimeric compound. 1. A process for the preparation of a composition comprising a contrast agent in a carrier , the process comprising the step of desalinating the composition by electrodeionization (EDI) using a wafer based EDI device.2. A process as claimed in wherein the contrast agent is an MR contrast agent or an X-ray contrast agent selected from a non-ionic iodinated monomeric compound and a non-ionic iodinated dimeric compound.3. A process as claimed in any of to wherein the contrast agent is selected from iohexol claim 1 , iodixanol and ioforminol.4. A process as claimed in any of to wherein the electrodeionization step takes place before or after the contrast agent is crystallized.5. A process as claimed in any of to wherein the contrast agent is iohexol claim 1 , the process comprising the step of desalinating a crude composition comprising iohexol by electrodeionization using a wafer based EDI device claim 1 , including the sequential steps of:(1) reducing the salt content in a crude composition which is the reaction mixture comprising Compound A, salts and iohexol, by EDI;(2) crystallizing iohexol from the composition of step (1).6. A process as claimed in any of to wherein the contrast agent is iodixanol claim 1 , the process comprising the step of desalinating a crude composition comprising iodixanol by electrodeionization using a wafer based EDI device claim 1 , including the sequential steps of:(1) reducing the salt content in a crude composition which is the reaction mixture comprising Compound A, salts and iodixanol, by EDI;(2) recovering Compound A in the composition of (1) after ...

Подробнее
Номер записи: 66
24-10-2013 дата публикации

ZEBRAFISH SEIZURE MODEL, METHOD FOR ESTABLISHING THE SAME, AND METHOD FOR SCREENING ANTIEPILEPTIC DRUG USING THE SAME

Номер: US20130283403A1
Автор: FU Tzu-Fun, LEE Gang-Hui
Принадлежит: NATIONAL CHENG KUNG UNIVERSITY

A zebrafish seizure model, a method for establishing the same, and a method for screening for antiepileptic drug using the same are disclosed. The method for establishing the zebrafish seizure model comprises the following steps: placing a zebrafish in a medium containing an inducing compound represented by the following formula (I) to induce seizure-like symptom in zebrafish: 2. The establishing method as claimed in claim 1 , wherein the zebrafish is a zebrafish embryo.3. The establishing method as claimed in claim 1 , wherein Ris a methyl or ethyl claim 1 , Ris a hydroxyl group claim 1 , methyl or ethyl claim 1 , and Ris an ether group having 1 to 6 carbon atoms.4. The establishing method as claimed in claim 1 , wherein Ris —C—O—C.6. The establishing method as claimed in claim 5 , wherein the medium is water.7. The establishing method as claimed in claim 1 , wherein a concentration of the inducing compound in the medium is 0.05 to 1.5 mM.9. The zebrafish seizure model as claimed in claim 8 , wherein the zebrafish is a zebrafish embryo.10. The zebrafish seizure model as claimed in claim 8 , wherein Ris a methyl or ethyl claim 8 , Ris a hydroxyl group claim 8 , methyl or ethyl claim 8 , Ris an ether group having 1 to 6 carbon atoms.11. The zebrafish seizure model as claimed in claim 8 , wherein Ris —C—O—C.13. The zebrafish seizure model as claimed in claim 12 , wherein the medium is a water.14. The zebrafish seizure model as claimed in claim 8 , wherein a concentration of the induced compound in the medium is 0.05 to 1.5 mM.16. The screening method as claimed in claim 15 , wherein the zebrafish is a zebrafish embryo.17. The screening method as claimed in claim 15 , wherein Ris a methyl or ethyl claim 15 , Ris a hydroxyl group claim 15 , methyl or ethyl claim 15 , Ris an ether group having 1 to 6 carbon atoms.18. The screening method as claimed in claim 15 , wherein Ris —C—O—C.20. The screening method as claimed in claim 19 , wherein the medium is a water.21. The ...

Подробнее
Номер записи: 67
31-10-2013 дата публикации

ANIMAL MODEL OF ANXIETY AND DEPRESSION

Номер: US20130287694A1
Автор: Sufka Kenneth J.
Принадлежит: UNIVERSITY OF MISSISSIPPI

This invention relates generally to animal models of anxiety and depression. Specifically, this invention relates to an in vivo high utility, high-throughput model for screening anxiolytic/antidepressant drugs in fowl chicks with stress vulnerability. This new animal model utilizes an inexpensive avian model, measures spontaneous behaviors in very young animals, and is capable of detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects. This new animal model is especially useful in detecting and/or differentiating a compound's anxiolytic and/or antidepressant effects in treatment-resistant subjects. Animal costs are less than 10% of rodent costs and the assay can be run in a high-throughput mode. 1. A method of identifying a candidate agent for the treatment of treatment-resistant depression , the method comprising:providing an experimental animal model of treatment-resistant depression;administering a candidate compound to at least one animal of said animal model; andevaluating one or more clinical parameters of treatment-resistant depression in said at least one animal of said animal model, wherein a candidate compound that is associated with an improvement in a clinical parameter of treatment-resistant depression is a candidate agent for the treatment of treatment-resistant depression.2. The method of claim 1 , wherein the animal model is an avian animal model.3. The method of claim 2 , wherein the avian animal model comprises fowl chicks with stress vulnerability.4. The method of claim 2 , wherein the avian animal model comprises Black Australorp chicks.5. A model system for treatment-resistant depression comprising an animal with stress vulnerability where said animal is insensitive to at least two classes of antidepressants selected from the group tricyclic antidepressants claim 2 , selective norepinephrine reuptake inhibitors (SNRI) claim 2 , and selective serotonin reuptake inhibitor (SSRI); and where said animal is sensitive to ...

Подробнее
Номер записи: 68
31-10-2013 дата публикации

CHONDROCYTE-LIKE CELL, AND METHOD FOR PRODUCING SAME

Номер: US20130287695A1
Автор: TSUMAKI Noriyuki
Принадлежит:

Disclosed is a cell which enables the reproduction of a cartilage tissue and has a proliferative ability. Also disclosed is a technique for providing a cell supply source which can be used in a definitive treatment of osteochondrosis deformans. A chondrocyte-like cell which has the same properties as those of a chondrocyte and can proliferate can be produced by selecting a combination of an Myc family gene and/or a Klf family gene and a SOX9 gene and introducing the combination into a somatic cell. The chondrocyte-like cell can be used for a medical purpose of cartilage regeneration. 1. A method for producing a cell with at least one of chondrocyte properties from a somatic cell , comprising the step of introducing into a somatic cell the following factors:a) a SOX9 gene;b) at least one of Myc family gene selected from the group consisting of c-Myc, L-Myc, and N-Myc; andc) at least one of Klf family gene selected from the group consisting of Klf4, Klf2 and Klf5.2. The method according to claim 1 , wherein the Myc family gene is a c-Myc gene.3. The method according to claim 1 , wherein the Klf family gene is a Klf4 gene.4. The method according to claim 1 , wherein the somatic cell originates in humans.5. The method according to claim 1 , wherein the somatic cell is a dermal fibroblast or an adipose tissue-derived stromal cell.610-. (canceled)11. A method for producing a cartilage tissue implant claim 1 , the method comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering the cell produced according to into a body of a mammal; and'}removing a cartilage tissue formed from the administered cell in the body of the mammal.12. A cartilage disease therapeutic method claim 1 , the method comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering the cell produced according to into a cartilage disease patient at a non-cartilage tissue site; and'}removing a cartilage tissue formed from the administered cell, and ...

Подробнее
Номер записи: 69
07-11-2013 дата публикации

METHODS FOR TREATING AND DIAGNOSING BLINDING EYE DISEASES

Номер: US20130295014A1
Автор: Boyd Shelley Romayne
Принадлежит:

This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA). 186.-. (canceled)88. The method of claim 87 , wherein the compound of Formula I is bindarit.89. The method of claim 87 , wherein the method further comprises administering an additional therapeutic agent claim 87 , wherein the additional therapeutic agent is one or more of an anti-vascular endothelial growth factor (VEGF) agent claim 87 , an angiotensin-converting enzyme (ACE) inhibitor claim 87 , a peroxisome proliferator-activated receptor (PPAR)-gamma agonist claim 87 , a renin inhibitor claim 87 , a steroid claim 87 , and an agent that modulates autophagy.90. The method of claim 87 , wherein the dry AMD is early stage AMD or atrophic AMD.91. A method for treating or preventing dry age related macular degeneration (AMD) claim 87 , comprising administering to a subject in need thereof an effective amount of methotrexate or a pharmaceutically acceptable salt thereof.92. The method of claim 91 , wherein the method further comprises administering an additional therapeutic agent claim 91 , wherein the additional therapeutic agent is one or more of an anti-vascular endothelial growth factor (VEGF) agent claim 91 , an angiotensin-converting enzyme (ACE) inhibitor claim 91 , a peroxisome proliferator-activated receptor (PPAR)-gamma agonist claim 91 , a renin inhibitor claim 91 , a steroid claim 91 , and an agent that modulates autophagy.93. The method of claim 91 , wherein the dry AMD is early stage AMD or atrophic AMD.95. The method of claim 94 , wherein the compound of Formula I is bindarit.96. The method of claim 94 , wherein the ...

Подробнее
Номер записи: 70
07-11-2013 дата публикации

Optically-Controlled CNS Dysfunction

Номер: US20130295015A1
Автор: Deisseroth Karl, Fenno Lief, Tye Kay
Принадлежит: The Board of Trustees of Leland Stanford Jnior Universtiy

Provided herein are animals expressing light-responsive opsin proteins in the basal lateral amygdala of the brain and methods for producing the same wherein illumination of the light-responsive opsin proteins causes anxiety in the animal. Also provided herein are methods for alleviating and inducing anxiety in an animal as well as methods for screening for a compound that alleviates anxiety in an animal. 1. A non-human animal comprising a light-responsive opsin expressed in glutamatergic pyramidal neurons of the basolateral amygdala (BLA) , wherein the opsin is an opsin which induces hyperpolarization by light , and wherein the selective illumination of the opsin in the BLA-centrolateral nucleus (BLA-CeL) induces anxiety of the animal.2. The animal of claim 1 , wherein the opsin is selected from the group consisting of NpHR claim 1 , BR claim 1 , AR claim 1 , and GtR3.3. The animal of claim 1 , further comprising a second light-responsive opsin expressed in glutamatergic pyramidal neurons of the BLA claim 1 , wherein the second opsin is an opsin that induces depolarization by light claim 1 , and wherein the selective illumination of the second opsin in the BLA-CeL reduces anxiety of the animal.4. The animal of claim 3 , wherein the second opsin is selected from the group consisting of ChR2 claim 3 , VChR1 claim 3 , and DChR.5. A non-human animal comprising a light-responsive opsin expressed in the glutamatergic pyramidal neurons of the basolateral amygdala (BLA) claim 3 , wherein the opsin is an opsin that induces depolarization by light claim 3 , and wherein the selective illumination of the opsin in the BLA-centrolateral nucleus (BLA-CeL) reduces anxiety of the animal.6. The animal of claim 5 , wherein the opsin is selected from the group consisting of ChR2 claim 5 , VChR1 claim 5 , and DChR.7. A recombinant vector for delivering a nucleic acid to glutamatergic pyramidal neurons of the basolateral amygdala (BLA) in an individual claim 5 , wherein the vector ...

Подробнее
Номер записи: 71
07-11-2013 дата публикации

Compstatin and analogs thereof for eye disorders

Номер: US20130296254A1
Автор: Cedric Francois, Pascal Deschatelets, Paul Olson
Принадлежит: Potentia Pharmaceuticals Inc

The present invention features the use of compstatin and complement inhibiting analogs thereof for treating and/or preventing age related macular degeneration and other conditions involving macular degeneration, choroidal neovascularization, and/or retinal neovascularization. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a second therapeutic agent. The invention also provides compositions comprising compstatin or a complement inhibiting analog thereof and a gel-forming material, e.g., soluble collagen, and methods of administering the compositions.

Подробнее
Номер записи: 72
07-11-2013 дата публикации

Nucleic acid construct for expression of oxidative stress indicator and use thereof

Номер: US20130298263A1
Автор: Daisuke Oikawa, Takao Iwawaki
Принадлежит: RIKEN Institute of Physical and Chemical Research

The present invention provides a nucleic acid construct for expressing an oxidative stress indicator comprising: a nucleic acid sequence encoding an Nrf2 protein-derived partial protein that comprises at least an Neh2 domain sequence and substantially lacks or is functionally deficient in an Neh1 domain sequence or an Neh1-Neh3 domain sequence; a stress-inducible promoter sequence positioned upstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein; and a nucleic acid sequence encoding a protein capable of generating a detectable signal, the nucleic acid sequence being positioned downstream of the nucleic acid sequence encoding an Nrf2 protein-derived partial protein. The present invention also provides a method for measuring oxidative stress and a method for screening for an anti-oxidative stress agent, using the nucleic acid construct.

Подробнее
Номер записи: 73
14-11-2013 дата публикации

ENGINEERED HUMAN ENDOSIALIN-EXPRESSING RODENTS

Номер: US20130305396A1
Автор: Grasso Luigi, Lin Jian Min, Nicolaides Nicholas C., Sass Philip M., TOMKOWICZ Brian E., Zhou Yuhong
Принадлежит:

Provided herein are rodents that express the human endosialin gene. In preferred embodiments, the rodent is a mouse. Preferably, the human endosialin gene is integrated into the native or endogenous endosialin gene locus. More preferably, the host rodent is null for the endogenous endosialin gene product. The human endosialin gene is preferably expressed in a similar development and disease response pattern as that of the native endosialin gene product in parental or wild type rodents. This feature makes these rodents useful for studying the effects of test agents to positively or negatively affect endosialin biology for therapeutic use. Use of human endosialin expressing rodents lacking native endosialin gene product (HUE rodents) is proposed as a strategy for developing agents that can positively or negatively affect the endosialin pathway and also serve as a screening tool to identify those agents that may be useful as human therapies. 1. A transgenic rodent comprising a nucleotide sequence encoding human endosialin integrated into the genome of said rodent.2. The transgenic rodent of wherein said nucleotide sequence comprises SEQ ID NO: 3.3. The transgenic rodent of wherein said human endosialin comprises the amino acid sequence of SEQ ID NO: 4.4. The transgenic rodent of wherein said rodent is a mouse.5. The transgenic rodent of wherein said nucleotide sequence is located within said rodent's endogenous endosialin gene locus.6. The transgenic rodent of wherein said rodent's endogenous endosialin gene is disrupted and therefore nonfunctional due to integration of said nucleotide sequence.7. The transgenic rodent of wherein said nucleotide sequence is under the control of said rodent's endogenous gene expression regulatory sequences.8. The transgenic rodent of further comprising a reporter gene or a selectable marker.9. A cell isolated from the transgenic rodent of .10. The cell of wherein said cell is isolated from normal tissue claim 9 , malignant tissue claim ...

Подробнее
Номер записи: 74
21-11-2013 дата публикации

BACTERIAL IMAGING AGENTS AND METHODS OF USING SAME

Номер: US20130309168A1
Автор: Ho Guojie
Принадлежит: VisEn Medical, Inc.

The invention provides a family of agents that target bacterial infection, which can be used as imaging agents or therapeutic agents. The agents can be used to image sites of bacterial infection as well as other physiological processes in a subject. 1. A bacterium targeting agent comprising:a. a bacterium targeting moiety comprising a positively charged moiety optionally substituted with an aliphatic, aromatic or heteroaromatic moiety; andb. an imaging reporter chemically linked, optionally through a linker (L) moiety to the bacterium targeting moiety.4. The agent of claim 1 , wherein the imaging reporter is selected from a group comprising: a fluorescent moiety claim 1 , a magnetic moiety claim 1 , and a radioisotope.5. The agent of claim 1 , wherein the imaging reporter bears a plurality of chemical modifying moieties.9. The agent of claim 1 , wherein the agent is fluorescent in the far-red or near-infrared wavelengths.11. The agent of claim 1 , wherein M is selected from the group consisting of a hydrogen claim 1 , alcohol claim 1 , sulfonate claim 1 , polysulfonate claim 1 , cysteic acid claim 1 , sulfonamide claim 1 , sulfoxide claim 1 , sulfone claim 1 , carboxylate claim 1 , ketone claim 1 , phosphonate claim 1 , phosphate; iminodiacetate claim 1 , ethylenediamine tetraacetic acid claim 1 , diethylenetriamine pentaacetic acid claim 1 , tetraazacyclododecane tetraacetic acid claim 1 , an amino acid or polyamino acid claim 1 , oligo- or polyethylene glycol claim 1 , amine claim 1 , quaternary ammonium ion claim 1 , sugars claim 1 , glucosamine claim 1 , galactosamine claim 1 , mannosamine claim 1 , polyethylene glycol (PEG) and derivatives thereof claim 1 , for example claim 1 , alkoxy polyethylene glycol (for example claim 1 , methoxypolyethylene glycol claim 1 , ethoxypolyethylene glycol and the like) claim 1 , branched polypropylene glycol claim 1 , polypropylene glycol claim 1 , a graft copolymer of poly-lysine and methoxypolyethyleneglycol claim 1 , ...

Подробнее
Номер записи: 75
21-11-2013 дата публикации

PRE-TARGETED NANOPARTICLE SYSTEM AND METHOD FOR LABELING BIOLOGICAL PARTICLES

Номер: US20130309171A1
Автор: Gunn Jonathan Whitney, Park Steven I., Press Oliver W., Zhang Miqin
Принадлежит: University of Washington through its Center for Commercialization

Nanoparticle system and method for labeling, detecting, and treating biological particles. In the method, targeting functionality (fusion protein) and therapeutic/imaging modalities (nanoparticle) are separated. 1. A method for labeling a biological particle , comprising:(a) contacting a biological particle with a fusion protein having a binding region having an affinity to a binding partner and a targeting region having an affinity toward the biological particle to provide a fusion protein-labeled biological particle; and(b) contacting the fusion protein-labeled biological particle with a nanoparticle comprising the binding partner to provide a nanoparticle-labeled biological particle.2. The method of claim 1 , wherein contacting the biological particle with a fusion protein comprises administering the fusion protein to a subject to be diagnosed or treated.3. The method of claim 2 , wherein administering the fusion protein comprises intravenous administration.4. The method of claim 1 , wherein the biological particle is a particle circulating in the vasculature of a living organism.5. The method of claim 1 , wherein the biological particle is a cell claim 1 , a bacterium claim 1 , a virus or viral particle claim 1 , or a biomarker.6. The method of claim 5 , wherein the cell is a stem cell claim 5 , a blood cell claim 5 , or a tissue cell.7. The method of claim 6 , wherein the stem cell is an embryonic stem cell or adult stem cell.812-. (canceled)13. The method of claim 5 , wherein the fusion protein binding region comprises a biotin binding region.14. The method of claim 5 , wherein the fusion protein binding region comprises an avidin claim 5 , a streptavidin claim 5 , a neutravidin claim 5 , or functional fragments thereof.15. The method of claim 5 , wherein the fusion protein targeting region comprises a single chain antibody or functional fragment thereof.16. (canceled)17. The method of claim 1 , wherein the nanoparticle further comprises an imaging agent.18. ( ...

Подробнее
Номер записи: 76
21-11-2013 дата публикации

CLEAVABLE FUNCTIONALIZED NANOPARTICLES

Номер: US20130309172A1
Автор: Berlin Jacob M., Suresh Anil K., Williams John
Принадлежит: CITY OF HOPE

Provided herein, inter alia, are compositions of functionalized nanoparticles and methods of using functionalized nanoparticles in treating, imaging, and/or detecting cancers. 1. A functionalized nanoparticle comprising a nanoparticle core and a nanoparticle coating , wherein:(i) said nanoparticle core is about 2 to about 35 nm in length; (a) a nanoparticle binding moiety bonded to said nanoparticle core;', '(b) a cleavage site covalently linked to said nanoparticle binding moiety; and', '(c) a water soluble moiety covalently linked to said cleavage site., '(ii) said nanoparticle coating comprises a plurality of hydrophilic moieties bonded to said nanoparticle core, wherein each of said hydrophilic moieties comprise2. The functionalized nanoparticle of claim 1 , wherein said water soluble moiety is a water soluble polymer moiety.3. The functionalized nanoparticle of claim 1 , wherein said nanoparticle core is about 3 to about 10 nm in length.4. The functionalized nanoparticle of claim 1 , wherein said nanoparticle core is an inorganic nanoparticle core.5. The functionalized nanoparticle of claim 1 , wherein said nanoparticle core is a metal nanoparticle core.6. The functionalized nanoparticle of claim 5 , wherein said metal nanoparticle core comprises titanium claim 5 , zirconium claim 5 , gold claim 5 , silver claim 5 , platinum claim 5 , cerium claim 5 , arsenic claim 5 , iron claim 5 , aluminum or silicon.7. The functionalized nanoparticle of claim 1 , wherein said nanoparticle core is a polymeric core.8. The functionalized nanoparticle of claim 1 , wherein said nanoparticle core comprises an outer shell layer and an inner layer claim 1 , wherein said outer shell layer is chemically distinct from said inner layer.9. The functionalized nanoparticle of claim 1 , further comprising a delivery agent bonded to said nanoparticle core.10. The functionalized nanoparticle of claim 1 , wherein said delivery agent is bonded to said nanoparticle core through a cleavable ...

Подробнее
Номер записи: 77
21-11-2013 дата публикации

Methods and Compositions for RNAi Mediated Inhibition of Gene Expression in Mammals

Номер: US20130312126A1
Автор: Kay Mark A., McCaffrey Anton
Принадлежит:

Methods and compositions are provided for modulating, e.g., reducing, coding sequence expression in mammals. In the subject methods, an effective amount of an RNAi agent, e.g., an interfering ribonucleic acid (such as an siRNA or shRNA) or a transcription template thereof, e.g., a DNA encoding an shRNA, is administered to a non-embryonic mammal, e.g., via a hydrodynamic administration protocol. Also provided are RNAi agent pharmaceutical preparations for use in the subject methods. The subject methods and compositions find use in a variety of different applications, including academic and therapeutic applications. 1. A method of reducing expression of a coding sequence in a target cell of a non-embryonic mammal , said method comprising:administering to said mammal an effective amount of an RNAi agent specific for said coding sequence to reduce expression of said coding sequence.2. The method according to claim 1 , wherein said RNAi agent is an interfering ribonucleic acid.3. The method according to claim 2 , wherein said interfering ribonucleic acid is a siRNA.4. The method according to claim 2 , wherein said interfering ribonucleic acid is a shRNA.5. The method according to claim 1 , wherein said RNAi agent is a transcription template of an interfering ribonucleic acid.6. The method according to claim 5 , wherein said transcription template is a deoxyribonucleic acid.7. The method according to claim 6 , wherein said deoxyribonucleic acid encodes a shRNA.8. The method according to claim 1 , wherein said non-embryonic mammal is an adult.9. The method according to claim 8 , wherein said non-embryonic mammal is a juvenile.10. The method according to claim 1 , wherein said RNAi agent is hydrodynamically administered to said non-embryonic mammal.11. The method according to claim 10 , wherein said RNAi agent is hydrodynamically administered to said non-embryonic mammal in conjunction with an RNAse inhibitor.1217-. (canceled)18. A method for introducing a ribonucleic acid ...

Подробнее
Номер записи: 78
28-11-2013 дата публикации

Sparc binding peptides and uses thereof

Номер: US20130315823A1
Автор: Vuong Trieu
Принадлежит: Abraxis Bioscience Llc

The invention provides SPARC and Albumin binding peptides for the targeting of disease sites, such as tumors, with therapeutic and diagnostic agents. In particular, compositions comprising SPARC binding peptide-Antibody Fc domain fusion proteins and methods of their use are disclosed.

Подробнее
Номер записи: 79
28-11-2013 дата публикации

LIPID-POLYMER HYBRID PARTICLES

Номер: US20130315831A1
Автор: Farokhzad Omid C., Langer Robert S., Shi Jinjun, Vilos Cristian, Votruba Alexander, XIAO Zeyu
Принадлежит:

A particle includes an aqueous core; a first amphiphilic layer surrounding the aqueous core; and a polymeric matrix surrounding the first amphiphilic layer. 1. A particle comprising:an aqueous core;a first amphiphilic layer surrounding the aqueous core; anda polymeric matrix surrounding the first amphiphilic layer.2. The particle of claim 1 , further comprising a second amphiphilic layer surrounding the polymeric matrix.3. The particle of claim 1 , wherein the particle has an average diameter between about 40 nm and about 400 μm.4. (canceled)5. The particle of claim 1 , wherein the first amphiphilic layer is a multilayer.6. The particle of claim 1 , wherein the first amphiphilic layer comprises naturally derived lipids claim 1 , surfactants claim 1 , or synthesized compounds with both hydrophilic and hydrophobic moieties.7. The particle of claim 1 , wherein the first amphiphilic layer comprises 1 claim 1 ,2-dimyristoleoyl-sn-glycero-3-ethylphosphocholine (EPC14:1).8. The particle of claim 1 , wherein the first amphiphilic layer has a thickness of about 1 nm to about 50 nm.9. The particle of claim 1 , wherein the polymeric matrix comprises poly(lactide-co-glycolide) (PLGA) claim 1 , a polyalkylene glycol claim 1 , or a polyester.10. The particle of claim 1 , wherein the polymeric matrix comprises polyethylenes claim 1 , polycarbonates claim 1 , polyanhydrides claim 1 , polyhydroxyacids claim 1 , polypropylfumerates claim 1 , polycaprolactones claim 1 , polyamides claim 1 , polyacetals claim 1 , polyethers claim 1 , polyesters claim 1 , poly(orthoesters) claim 1 , polycyanoacrylates claim 1 , polyvinyl alcohols claim 1 , polyurethanes claim 1 , polyphosphazenes claim 1 , polyacrylates claim 1 , polymethacrylates claim 1 , polycyanoacrylates claim 1 , polyureas claim 1 , polystyrenes claim 1 , or polyamines claim 1 , or combinations thereof.1113.-. (canceled)14. The particle of claim 9 , wherein the polyester is poly(lactide-co-glycolide) (PLGA) claim 9 , polylactic ...

Подробнее
Номер записи: 80
28-11-2013 дата публикации

ANTI-LIGHT ANTIBODY THERAPY FOR INFLAMMATORY BOWEL DISEASE

Номер: US20130315913A1
Автор: Zhang Meng
Принадлежит: SANOFI

The present invention provides safe therapeutic doses of an antagonist of human LIGHT (lymphotoxin-like, exhibits inducible expression and competes with Herpes Virus Glycoprotein D for Herpes Virus Entry Mediator (HVEM), a receptor expressed by T lymphocytes), as well as methods of monitoring whether a therapeutic dose of an anti-LIGHT antagonist is safe. 1. A maximal safe therapeutic dose of a LIGHT antagonist which , following administration of a single dose to a human subject , has one or more of the properties selected from the group consisting of:{'sub': 'last', '(a) an area under the plasma concentration versus time curve calculated using the trapezoidal method from time zero to real time (AUC) from about 100 mg·day/L to about 6000 mg·day/L;'}(b) an area under the plasma concentration versus time curve extrapolated to infinity (AUC) from about 150 mg·day/L to about 6000 mg·day/L;{'sub': 'max', '(c) a maximum plasma concentration observed (C) from about 3.5 mg/L to about 175 mg/L;'}{'sub': 'max', '(d) a first time to reach a maximum plasma concentration (t) from about 4 days to about 9 days; and'}{'sub': '1/2', 'sup': 'Z', '(e) a time to reach terminal half life (t) from about 3 days to about 47 days.'}2. The dose of claim 1 , wherein the LIGHT antagonist is an antibody or antigen-binding fragment that specifically binds LIGHT.3. The dose of claim 1 , wherein the antibody or antigen-binding fragment comprises:(a) heavy and light chain CDR sequences from the HCVR/LCVR sequence pair of SEQ ID NOs: 10/11;(b) three heavy chain complementarity determining region (HCDR) sequences comprising SEQ ID NOs: 1, 2, and 3, respectively, and three light chain complementarity determining (LCDR) sequences comprising SEQ ID NOs: 4, 5, and 6, respectively; or(c) an HCVR having the amino acid sequence of SEQ ID NO: 10 and an LCVR having the amino acid sequence of SEQ ID NO: 11.4. The dose of claim 1 , wherein the therapeutic dose is equal to or less than about 1200 mg.5. The dose ...

Подробнее
Номер записи: 81
28-11-2013 дата публикации

Antibodies and immunoconjugates and uses therefor

Номер: US20130316402A1
Автор: Aya Jakobovits, Bonnee Rubinfeld, Mark S. Dennis, Paul Polakis
Принадлежит: Genentech Inc

Anti-STEAP-1 antibodies and immunoconjugates thereof are provided. Methods of using anti-STEAP-1 antibodies and immunoconjugates thereof are provided.

Подробнее
Номер записи: 82
28-11-2013 дата публикации

Novel Inflammation to vivo model

Номер: US20130318641A1
Автор: Antonio Iglesias, Claas Aiko Meyer, Javier Cote-Sierra
Принадлежит: Hoffmann La Roche Inc

The present invention relates to a non-human animal deficient in the N-terminal domain of the IL-33 gene. Also provided herein is the use of said non-human animal as an in vivo model of inflammatory diseases, especially with regard to screening methods for anti-inflammatory compounds, and methods for evaluating and optimising the pharmacological properties of a given anti-inflammatory compound.

Подробнее
Номер записи: 83
28-11-2013 дата публикации

Methods of Screening Agents for Activity Using Teleosts

Номер: US20130318642A1
Автор: McGrath Patricia, Parng Chuenlei, Serbedzija George N.
Принадлежит:

The present invention provides methods of screening an agent for activity using teleosts. Methods of screening an agent for angiogenesis activity, toxic activity and an effect cell death activity in teleosts are provided. Methods of screening an agent for an activity in the brain or central nervous system in zebrafish are provided. The invention further provides high throughput methods of screening agents in multi-well plates. 1. A method of screening an agent for an effect on a brain or central nervous system (CNS) disease or disorder in a zebrafish in vivo , the method comprising:(a) administering a compound to the zebrafish, wherein the compound induces a phenotype in the zebrafish that mimics the brain or CNS disease or disorder;(b) administering the agent to the zebrafish;(c) detecting a response in the brain or CNS of the zebrafish; and(d) comparing the response in the brain or CNS of the agent-treated zebrafish with a response in the brain or CNS of the compound-treated zebrafish administered with no agent or a control agent, wherein a difference in the response in the brain or CNS of the agent-treated zebrafish compared to the response in the brain or CNS of the untreated or control agent-treated zebrafish indicates the agent has an effect on the brain or CNS disease or disorder.2. A method of screening an agent for an ability to affect blood brain barrier (BBB) permeability in a zebrafish in vivo , the method comprising:(a) administering the agent to the zebrafish of age at least 3 days post-fertilization;(b) detecting a response in the zebrafish; and(c) comparing the response in the agent-treated zebrafish with a response in a zebrafish administered with no agent or a control agent, wherein a difference in the response in the agent-treated zebrafish compared the untreated or control agent-treated zebrafish indicates the agent has the ability to affect BBB permeability.310-. (canceled)11. The method of claim 2 , wherein the agent is administered to the ...

Подробнее
Номер записи: 84
28-11-2013 дата публикации

DIAGNOSIS AND THERAPEUTIC EPITOPE, AND TRANSGENIC PLANT

Номер: US20130318648A1
Автор: ANDERSON ROBERT PAUL, HILL ADRIAN VIVIAN, JEWELL DEREK PARRY
Принадлежит: ISIS INNOVATION LIMITED

A method of diagnosing coeliac disease, or susceptibility to coeliac disease, in an individual comprising: (a) contacting a sample from the host with an agent selected from (i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, (ii) an epitope comprising sequence comprising: SEQ ID NO: 1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO: 3, which epitope is an isolated oligopeptide derived from a gliadin protein, (iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or (iv) a product comprising two or more agents as defined in (i), (ii) or (iii), and (b) determining in vitro whether T cells in the sample recognise the agent; recognition by the T cells indicating that the individual has, or is susceptible to, coeliac disease. Therapeutic compositions which comprise the epitope and gliadin proteins which do not cause coeliac disease are also provided. 1. A method of diagnosing coeliac disease , or susceptibility to coeliac disease , in an individual comprising:(a) contacting a sample from the host with an agent selected from(i) the epitope comprising sequence which is: SEQ ID NO: 1 or 2, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3,(ii) an epitope comprising sequence comprising: SEQ ID NO:1, or an equivalent sequence from a naturally occurring homologue of the gliadin represented by SEQ ID NO:3, which epitope is an isolated oligopeptide derived from a gliadin protein,(iii) an analogue of (i) or (ii) which is capable of being recognised by a T cell receptor that recognises (i) or (ii), which in the case of a peptide analogue is not more than 50 amino acids in length, or(iv) a product comprising ...

Подробнее
Номер записи: 85
05-12-2013 дата публикации

METHODS OF DETECTING PANCREOBILIARY DUCTAL LEAKS

Номер: US20130323174A1
Автор: Purich Edward E.
Принадлежит:

The present invention is directed to a method for identifying ductal leaks during pancreobiliary surgery in a human patient. The invention comprises the steps of: administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; and observing the patient during the surgery for the presence of pancreobiliary ductal leaks. 1. A method for identifying ductal leaks during pancreobiliary surgery in a human patient , comprising the steps of:administering to a human patient undergoing pancreobiliary surgery an effective amount of a pharmaceutical composition comprising secretin and a pharmaceutically acceptable carrier; andobserving said patient during said surgery for the presence of pancreobiliary ductal leaks.2. The method of claim 1 , wherein said pancreobiliary surgery is selected from the group consisting of the Whipple Procedure claim 1 , distal pancreatectomy claim 1 , total pancreatectomy claim 1 , pancreatic transplantation claim 1 , surgery on the pancreas due to injury claim 1 , duodectomy claim 1 , removing or rerouting pancreatic ductal tubes claim 1 , and combinations thereof.3. The method of claim 1 , wherein the dosage of secretin administered to said patient in said pharmaceutical composition comprises ranges from 0.1 to 0.4 micrograms per kilogram bodyweight of said patient.4. The method of claim 1 , wherein the dosage of secretin administered to said patient in said pharmaceutical composition comprises ranges from 0.15 to 0.3 micrograms per kilogram bodyweight of said patient.5. The method of claim 1 , wherein the dosage of secretin administered to said patient in said pharmaceutical composition is approximately 0.2 micrograms per kilogram bodyweight of said patient.6. The method of claim 1 , wherein said secretin is a naturally occurring form of secretin.7. The method of claim 1 , wherein said secretin is a synthetic form of secretin.8. ...

Подробнее
Номер записи: 86
05-12-2013 дата публикации

USE OF 31P NMR SPECTROSCOPY OF WHOLE HEART ENERGETICS FOR DETECTION OF DRUG-INDUCED CARDIOTOXICITY

Номер: US20130323175A1
Автор: Henderson Kim A., Roche Brian M.
Принадлежит: BATTELLE MEMORIAL INSTITUTE

Disclosed are methods of determining cardiac toxicity of a compound of interest, wherein a heart or cardiac cell of a mammal may be contacted a compound of interest and peak levels of one or more indicators of cardiac energetics after administration of the compound may be detected using P NMR before and after exposure to a compound known to stress the heart or cardiac cell. Detection of the indicators of cardiac energetics may be combined with other indicators of cardiac function such as, for example, contractility, relaxation, heart rate, and/or conduction velocity to arrive at a profile capable of predicting the cardiotoxicity of potential therapeutics. 1. A method of determining cardiac toxicity of a compound of interest , comprising the steps ofa. optionally, i) determining from a heart or cardiac cell of a mammal peak levels of one or more indicators of cardiac energetics selected from inorganic phosphate, phosphocreatine, ATPγ, or a combination thereof; and ii) one or more indicators of cardiac function selected from contractility, relaxation, heart rate, conduction velocity, or a combination thereof, before administration of said compound of interest to the heart or cardiac cell;b. contacting said heart or cardiac cell of a mammal with a compound of interest;c. determining after step (b), i) peak levels of said one or more indicators of cardiac energetics after administration of said compound of interest to a heart or cardiac cell of a mammal; and, optionally, ii) one or more indicators of cardiac function selected from contractility, relaxation, heart rate, conduction velocity, or a combination thereof;d. contacting said heart or cardiac cell of said mammal after step (b) with an agent known to cause an increase in cardiac function, said cardiac function selected from contractility, relaxation, heart rate, conduction velocity, or a combination thereof;e. measuring after step (d), i) peak levels of said one or more indicators of cardiac energetics after ...

Подробнее
Номер записи: 87
05-12-2013 дата публикации

GALECTIN-9-SECRETING CELL, AND PRODUCTION METHOD AND USE OF THE SAME

Номер: US20130323176A1
Автор: Arikawa Tomohiro, Hirashima Mitsuomi, Kadowaki Takeshi, Niki Toshiro, Oomizu Souichi
Принадлежит:

The object of the present invention is to provide a cell that can exhibit physiological activity based on galectin-9, a method for producing the cell, and use of the cell. In order to achieve the above object, the cell of the present invention contains galectin-9, and the galectin-9 is expressed on a cell surface. 1. A cell not comprising DNA coding for galectin-9 having a signal peptide , whereinthe cell has an ability to secrete galectin-9 and expresses the galectin 9 on a cell surface.2. The cell according to claim 1 , which is a T cell.3. The cell according to claim 2 , which is a CD4 positive T cell.4. The cell according to claim 3 , which is a follicular B helper T cell (TFH cell).5. The cell according to claim 3 , wherein increase in expression level of CD25 and secretion of at least one of galectin-9 and interleukin 10 (IL-10) are induced by T cell receptor (TCR) stimulation.6. The cell according to claim 3 , which does not express Foxp3.7. The cell according to claim 2 , which is a γδT cell.8. The cell according to claim 1 , which is a natural killer cell (NK cell).9. The cell according to claim 1 , which is a B cell.10. The cell according to claim 1 , which is a NKT cell.11. The cell according to claim 1 , which is a conventional dendritic cell (cDC).12. The cell according to claim 1 , which is a plasmacytoid dendritic cell (pDC).13. The cell according to claim 1 , which is a pDC-like macrophage (pDC-Mφ.14. A method for producing the cell according to claim 1 , the method comprising:administering galectin-9 to an animal, thus inducing galectin-9 expression on a cell surface of at least one cell in the animal.15. A method for producing the cell according to claim 1 , the method comprising:culturing one or more cells of an animal in the presence of galectin-9, thus inducing galectin-9 expression on a cell surface of at least one of the cells.16. The production method according to claim 15 , whereinthe cells of the animal comprise a cell expressing galectin-9 ...

Подробнее
Номер записи: 88
12-12-2013 дата публикации

Pluripotent Cells From Rat and Other Species

Номер: US20130333058A1
Автор: Smith Austin Gerard, Ying Qi-Long
Принадлежит: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

Pluripotent cells are derived and maintained in a self-renewing state in serum-free culture medium comprising a MEK inhibitor, a GSK3 inhibitor and an antagonist of an FGF receptor. 1160-. (canceled)161. A genetically engineered rat obtained by a method comprisinggenetically modifying a rat pluripotent cell expressing two or more of Nanog, Oct4, FGF4, and Sox-2; andintroducing the pluripotent cell into a rat embryo to produce a genetically modified rat, wherein the rat pluripotent cell contributes to the germline of the genetically modified rat.162. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell expresses Nanog claim 161 , Oct4 claim 161 , and Sox-2.163. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell further expresses alkaline phosphatase.164. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell expresses Rex1 claim 161 , Stella claim 161 , FGF4 claim 161 , and Sox-2.165. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell does not express FGF5.166. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell is capable of forming a teratoma or teratocarcinoma in which differentiated cells from all three germ layers are present.167. The genetically engineered rat of claim 161 , wherein the rat pluripotent cell is capable of growth and/or proliferation as a single cell in culture.168. The genetically engineered rat of claim 161 , wherein the pluripotent rat cell is derived from a blastocyst by a method comprising:culturing the blastocyst in the presence of a MEK inhibitor and a GSK3 inhibitor, to obtain an inner cell mass;isolating and dissociating the primary outgrowths of the inner cell mass;isolating a cell or cells from the dissociated primary outgrowths of the inner cell mass; andculturing the isolated cell or cells in the presence of a MEK inhibitor, a GSK3 inhibitor, and an antagonist of an FGF receptor.169. The genetically ...

Подробнее
Номер записи: 89
19-12-2013 дата публикации

FORMULATION OF ACOUSTICALLY ACTIVATABLE PARTICLES HAVING LOW VAPORIZATION ENERGY AND METHODS FOR USING SAME

Номер: US20130336891A1
Автор: Borden Mark A., Dayton Paul A., Matsunaga Terry O., Sheeran Paul S.
Принадлежит: The University of North Carolina at Chapel Hill

Formulation of acoustically activatable particles having low vaporization energy and methods for using same are disclosed. According to one aspect, a method of producing particles of materials includes, with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one of: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion. The droplet or emulsion so created is an activatable phase change agent that is stable at room temperature and pressure. 1. A method of producing particles of materials , comprising: causing the first substance to condense to a liquid phase, and extruding or emulsifying the first substance into or in the presence of a second substance to create a droplet or emulsion in which the first substance is encapsulated by the second substance; or', 'extruding or emulsifying the first substance into or in the presence of a second substance to create a bubble in which the first substance is encapsulated by the second substance and wherein at least some of the first substance is in a gaseous phase, and causing the first substance to condense to a liquid phase, which causes the bubble to transform into a droplet or emulsion;, 'with a first substance that includes at least one component that is a gas at room temperature and atmospheric pressure, performing one ofwherein the droplet or emulsion is an activatable phase ...

Подробнее
Номер записи: 90
26-12-2013 дата публикации

EFFICIENT SYNTHESIS OF ETHYLENEDICYSTEINE-SUGAR CONJUGATES FOR IMAGING AND THERAPY

Номер: US20130343995A1
Автор: YANG David J., Yu Dong-Fang
Принадлежит:

Novel methods of synthesis of ethylenedicysteine-sugar conjugates and therapeutic and diagnostic applications of such conjugates are disclosed. Methods of synthesizing these conjugates in high purity are also presented as using starting materials such as thiazolidine carboxylic acid. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these conjugates prepared herein, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia. 1. A method of preparing a thiazolidine-sugar conjugate comprising admixing an amino sugar with a thiazolidine carboxylic acid , thereby producing the thiazolidine-sugar conjugate.2. The method of claim 1 , further comprising reducing the thiazolidine-sugar conjugate with a reducing agent comprising an alkali metal and an electron source to thereby provide an ethylenedicysteine-sugar conjugate.3. The method of claim 1 , wherein the amino sugar is an amino hexose or an amino pentose.4. The method of claim 3 , wherein the amino hexose is an amino derivative of glucose claim 3 , galactose claim 3 , mannose claim 3 , idose claim 3 , talose claim 3 , altrose claim 3 , allose claim 3 , gulose or fructose.5. The method of claim 4 , wherein the amino hexose is glucosamine.6. The method of claim 3 , wherein the amino pentose is an amino derivative of ribose claim 3 , xylose claim 3 , arabinose or lyxose.7. The method of claim 1 , wherein the amino sugar is a sugar having an amino group positioned at the 2′ position of the sugar.8. The method of claim 1 , wherein hydroxyl groups of the amino sugar are protected.9. The method of claim 8 , wherein the amino sugar is 1 claim 8 ,3 claim 8 ,4 claim 8 ,6-tetra-O-acetyl-2-amino-α-D-glucopyranose hydrochloride.10. The method of claim 1 , wherein the admixing is carried out in an organic solvent.11. The method of claim 10 , wherein the organic solvent is dimethylformamide claim 10 , dimethylsulfoxide claim 10 , dioxane claim 10 , ...

Подробнее
Номер записи: 91
26-12-2013 дата публикации

TRANSGENIC VON WILLEBRAND FACTOR ANIMALS AND USES THEREOF

Номер: US20130347134A1
Автор: Chen Jianchun, Diacovo Thomas
Принадлежит:

The present invention provides, inter alia, transgenic non-human animals, such as transgenic mice. The animals contain in their genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide, which polypeptide forms a thrombus when in the presence of human platelets. Nucleic acid sequences and vectors for generating the transgenic non-human animals, and methods for using the transgenic non-human animals are provided as well. Chimeric VWF proteins are also provided. 1. A transgenic non-human animal comprising in its genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide , wherein the transgenic non-human animal expresses the VWF and forms a thrombus when in the presence of human platelets.2. The transgenic non-human animal according to claim 1 , wherein the VWF polypeptide comprises amino acids 1240P through 1481G of SEQ ID NO:6.3. The transgenic non-human animal according to claim 1 , wherein the VWF polypeptide is at least 90% identical to the amino acid sequence depicted in SEQ ID NO:25.4. The transgenic non-human animal according to claim 1 , wherein the polynucleotide encodes a VWF to which AvW3 specifically binds.5. The transgenic non-human animal according to claim 1 , wherein the animal is selected from the group consisting of mouse claim 1 , rat claim 1 , hamster claim 1 , guinea pig claim 1 , rabbit claim 1 , dog claim 1 , goat claim 1 , horse claim 1 , and monkey.6. The transgenic non-human animal according to claim 1 , wherein the animal is a mouse.7. A transgenic mouse comprising in its genome a polynucleotide encoding a von Willebrand factor (VWF) polypeptide claim 1 , wherein the transgenic mouse expresses the VWF and forms a thrombus when in the presence of human platelets.8. The transgenic mouse according to claim 7 , wherein the VWF polypeptide comprises amino acids 1240P through 1481G of SEQ ID NO:6.9. The transgenic mouse according to claim 7 , wherein the VWF polypeptide is at least 90% identical to the amino acid ...

Подробнее
Номер записи: 92
16-01-2014 дата публикации

Caged cell penetrating peptide-polymer conjugates for diagnostic and therapeutic applications

Номер: US20140017169A1
Автор: Ayelet David, Gonen Ashkenasy, Yossi Shamay
Принадлежит: Ayelet David, Gonen Ashkenasy, Yossi Shamay

The caged cell-penetrating peptide (cCPP) conjugates of this invention are ideal for intracellular delivery of a broad variety of cargoes including various nanoparticulate pharmaceutical carriers (liposomes, micelles, microparticles, nanoparticles, polymer-conjugates). The conjugates comprise a detectable agent or a therapeutic agent, and the conjugates provide a novel strategy for site-specific delivery of the same to appropriate tissues in the subject. Versatile application of the conjugates in diagnostics and imaging is described.

Подробнее
Номер записи: 93
16-01-2014 дата публикации

METHODS FOR THE TREATMENT OF TINNITUS INDUCED BY COCHLEAR EXCITOTOXICITY

Номер: US20140017172A1
Автор: GUITTON Matthieu, Puel Jean-Luc, Pujol Remy, Ruel Jerome, Wang Jing
Принадлежит:

The invention relates to methods for the prevention and/or treatment of tinnitus induced by cochlear excitotoxicity. In these methods, a pharmaceutical composition comprising an NMDA receptor antagonist is administered to an individual in need of such treatment by appropriate devices and/or formulations for local administration to the inner ear. The tinnitus to be prevented and/or treated may be provoked by acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more ototoxic medications, sudden deafness, or other cochlear excitotoxic-inducing occurrence. The invention also relates to method for the identification of compounds effective in the treatment and prevention of tinnitus by a novel screening method incorporating an electrophysiological test method. 19.-. (canceled)10. An electrophysical method for identifying compounds effective in the treatment of tinnitus , said method comprising:a) providing: i) an animal exhibiting tinnitus as is indicated by an ensemble spontaneous activity (ESA) with a spectral peak centered at about 200 to 250 Hz and ii) a test compound;b) administering said test compound to said animal, and;c) measuring the ESA of the animal to determine if tinnitus is reduced wherein the reduction of the spectral peak at about 200 to 250 Hz is indicative of whether tinnitus is reduced or eliminated.1121.-. (canceled) 1. Field of the InventionThis invention relates to methods for the delivery of pharmaceutical compounds to the inner ear for the treatment of tinnitus induced by cochlear excitotoxicity. Specifically, this invention relates to the local administration of N-Methyl-D-Aspartate (NMDA) receptor antagonists to the inner ear to suppress the NMDA receptor mediated aberrant activity of the auditory nerve following acute, repeated or prolonged or chronic occurrences of cochlear excitotoxicity provoked by incidents such as acoustic trauma, presbycusis, ischemia, anoxia, treatment with one or more certain ototoxic medications or ...

Подробнее
Номер записи: 94
23-01-2014 дата публикации

IMMUNOTHERAPY FOR IMMUNE SUPPRESSED PATIENTS

Номер: US20140023593A1
Автор: Hadden John W.
Принадлежит:

A diagnostic skin test for predicting treatment outcome, consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A kit for performing a skin test consisting essentially of an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. A method of performing a skin test on a patient, consisting essentially of the steps of administering an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and predicting a treatment outcome. Methods of detecting defects in monocyte or T lymphocyte function, including the steps of administering an effective amount of an NCM or T lymphocyte mitogen of muromonab-CD3 to skin, analyzing results of the skin test, and detecting at least one defect in monocyte or T lymphocyte function. A mechanism for indicating a functioning efferent or afferent limb of an immune system, including a diagnostic skin test including an effective amount of an NCM or a T lymphocyte mitogen of muromonab-CD3. 142.-. (canceled)43. A method for performing a skin test on a patient , the method comprising the steps of:a) administering an effective amount of muromonab-CD3 to the skin of a patient, andb) analyzing the skin of the patient for the presence or absence of erythema.44. The method of claim 43 , wherein the muromonab-CD3 is administered intradermally.45. The method of claim 43 , wherein the muromonab-CD3 is administered to the skin of the forearm.46. The method of claim 44 , wherein the muromonab-CD3 is administered to the skin of the forearm.47. The method of claim 43 , wherein the effective amount of muromonab-CD3 is 0.1 to 100 ng of muromonab-CD3.48. The method of claim 43 , wherein the skin of the patient is analyzed 6-48 hours after administration of the muromonab-CD3.49. The method of claim 48 , wherein the skin of the patient is analyzed 24 hours after administration of the muromonab-CD3.50. The method of claim 43 , wherein the patient ...

Подробнее
Номер записи: 95
30-01-2014 дата публикации

Methods for monitoring physiological status of a body organ

Номер: US20140033332A1
Автор: Berggren Per-Olof
Принадлежит:

The present invention provides method for monitoring physiological status of an organ in a subject by monitoring morphological changes over time in transplanted tissue on an eye of the subject. 1. A method for monitoring physiological status of an organ in a subject , comprising monitoring morphological changes over time in transplanted tissue on an eye of the subject , wherein the tissue is from an organ of interest , and wherein the morphological changes over time in the transplanted tissue on the eye of the subject indicate a physiological status of the organ of interest in the subject.2. The method of claim 1 , wherein the method is used to monitor efficacy of a course of treatment for a disorder in the subject.3. The method of claim 2 , wherein the course of treatment comprises administration of a therapeutic to the subject claim 2 , and wherein the method monitors efficacy of the therapeutic in the subject.4. The method of claim 2 , wherein the course of treatment comprises a diet and/or an exercise regimen claim 2 , and wherein the method monitors efficacy of the diet and/or exercise regimen in the subject.5. The method of claim 1 , wherein the transplanted tissue is obtained from the subject.6. The method of claim 1 , wherein the organ of interest is selected from the group consisting of pancreas claim 1 , lung claim 1 , heart claim 1 , brain claim 1 , kidney claim 1 , liver claim 1 , small intestine claim 1 , large intestine claim 1 , colon claim 1 , stomach claim 1 , gall bladder claim 1 , esophagus claim 1 , ureter claim 1 , urethra claim 1 , ovary claim 1 , uterus claim 1 , breast claim 1 , spinal cord claim 1 , prostate claim 1 , hypothalamus claim 1 , adrenal gland claim 1 , pituitary gland claim 1 , thyroid gland claim 1 , parathryroid gland claim 1 , pineal gland claim 1 , spleen claim 1 , thymus claim 1 , rectum claim 1 , mammary gland claim 1 , seminal vesicles claim 1 , glomeruli claim 1 , fat tissue claim 1 , tumor claim 1 , and testes.7. The ...

Подробнее
Номер записи: 96
06-02-2014 дата публикации

PRUSSIAN BLUE BASED NANOPARTICLE AS MULTIMODAL IMAGING CONTRAST MATERIAL

Номер: US20140037552A1
Автор: Máthé Domokos, Szigeti Krisztián
Принадлежит:

The invention relates to a Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating. The invention relates furthermore to a process for the preparation of said nanoparticle, and the use thereof as imaging contrast material or in the therapy. 1. A Prussian Blue based nanoparticle comprising a Prussian Blue based metal core doped with one or more metal isotope and an organic biocompatible coating.2. A Prussian Blue based nanoparticle according to claim 1 , wherein said metal core comprises Prussian Blue or one or more Prussian Blue analogue of the formula{'br': None, 'sub': x', 'm', '6', 'n, 'AM′[M(CN)]'}whereinA denotes a metal selected from the group consisting of Li, Na, K, Rb, Cs, Fr and Tl,M denotes a metal selected from the group consisting of V, Cr, Mn, Fe, Co, Ni, Cu, Ga, Zr, Nb, Mo, Ru, Cd, In, Hf, Ta, W, Os and Hg,M′ denotes a metal selected from the group consisting of Ca, V, Cr, Mn, Fe, Co, Ni, Cu, Zn, Ga, Sr, Zr, Nb, Mo, Ru, Rh, Pd, Ag, Cd, In, Lu, Ba, Hf, Ta, W, Os, Pt, Hg, La, Eu, Gd, Tb, Dy and Ho,m denotes 0 to 5,x denotes 0 to 5, andn denotes 0.5 to 10.3. A Prussian Blue based nanoparticle according to claim 1 , wherein said metal isotope is selected from the group consisting of Li claim 1 , Na claim 1 , K claim 1 , Rb claim 1 , Cs claim 1 , Fr claim 1 , Ga claim 1 , In claim 1 , Tl claim 1 , Ca claim 1 , Sc claim 1 , V claim 1 , Cr claim 1 , Mn claim 1 , Fe claim 1 , Co claim 1 , Ni claim 1 , Cu claim 1 , Zn claim 1 , Sr claim 1 , Y claim 1 , Zr claim 1 , Nb claim 1 , Mo claim 1 , Ru claim 1 , Rh claim 1 , Pd claim 1 , Ag claim 1 , Ba claim 1 , La claim 1 , Stn claim 1 , Eu claim 1 , Gd claim 1 , Tb claim 1 , Dy claim 1 , Ho claim 1 , Lu claim 1 , Hf claim 1 , Ta claim 1 , W claim 1 , Re claim 1 , Os claim 1 , Ir claim 1 , Pt claim 1 , Au claim 1 , Hg claim 1 , Pb and Bi.4. A Prussian Blue based nanoparticle according to claim 1 , wherein said biocompatible ...

Подробнее
Номер записи: 97
06-02-2014 дата публикации

Genetically Modified Rat Models for Obesity and Diabetes

Номер: US20140041063A1
Автор: Crawford John Stuart, Cuppen Edwin, Ostertag Eric M.
Принадлежит: Transposagen Biopharmaceuticals, Inc.

This invention relates to a genetically modified or chimeric rat cell whose genome comprises chromosomal alleles of an obesity-diabetes gene (especially, the Mc4r gene or Lep gene), wherein at least one of the two alleles contains a mutation, or the progeny of this cell. The obesity or diabetes gene may affect any of the pathways of obesity and diabetes. The obesity or diabetes gene may predispose the rat to a phenotype of obese and diabetic, lean and diabetic, obese and non-diabetic, non-obese and diabetic or any of the combinations thereof. In another aspect, the invention relates to a desired rat or a rat cell which contains a predefined, specific and desired alteration rendering the rat or rat cell predisposed to obesity or diabetes. 1. A genetically modified non-human mammal , or progenies thereof , at least some of whose cells comprise a genome comprising a genetic mutation in one or more genes that causes the mammal to have a greater susceptibility to develop obesity , diabetes or both than a mammal not comprising the genetic mutation.2. The genetically modified nonhuman mammal of claim 1 , wherein the mammal is a chimeric mammal.3. The genetically modified nonhuman mammal of claim 1 , wherein the mammal is a rat.4. The genetically modified nonhuman mammal of claim 1 , wherein one or more obesity-diabetes genes or loci are misexpressed.5. The genetically modified nonhuman mammal of claim 1 , wherein one or more obesity-diabetes genes are conditionally misexpressed.6. The non-human animal model of claim 1 , wherein the misexpression results in decreased expression of one or more obesity-diabetes gene products.7. The genetically modified nonhuman mammal of claim 1 , wherein the one or more genes encoding an obesity-diabetes gene product is disrupted.8. The genetically modified nonhuman mammal claim 1 , wherein all alleles on the genome of the obesity-diabetes gene are disrupted.9. The genetically modified nonhuman mammal of claim 1 , wherein the obesity- ...

Подробнее
Номер записи: 98
06-02-2014 дата публикации

Animal Model of Central Neuropathic Pain and Methods of Making and Using the Same

Номер: US20140041065A1
Автор: Falci Scott P.
Принадлежит:

The present disclosure describes an animal model of central neuropathic pain relevant to spinal cord injury, as well as methods of using the model to screen for therapeutic agents and to test existing therapies. 124-. (canceled)25. A rodent model of central neuropathic pain , the rodent comprising a partial injury to the dorsal horn that is the result of dorsal root entry zone (DREZ) avulsion at T13 , wherein the rodent exhibits an increased pain response while maintaining sensation and motor control in the affected territory , wherein the rodent lacks a spinal cord injury compromising motor or sensory tracts of the spinal cord , and wherein the rodent exhibits below-level pain.26. A rodent model of central neuropathic pain , comprising a rodent that exhibits below-level pain comprising an increased pain response to stimulation of a target , wherein the rodent comprises a partial injury of the dorsal horn that is the result of dorsal root entry zone (DREZ) avulsion at T13 , wherein said rodent exhibits aberrant activity of the spinal cord at a level rostral to the level at which the majority of sensory neurons serving the target enter the spinal cord , and wherein the rodent lacks a spinal cord injury compromising motor or sensory tracts of the spinal cord.27. A rodent model of below-level pain , the rodent comprising a partial injury of the dorsal horn that is the result of dorsal root entry zone (DREZ) avulsion at T13 , and exhibits below-level pain comprising an increased pain response.28. The rodent model according to claim 25 , wherein DREZ fibers are bilaterally avulsed at one or more spinal segments.29. The rodent model according to claim 25 , wherein the DREZ fibers that are avulsed include DREZ fibers at T13.30. The rodent model according to claim 25 , wherein the DREZ fibers that are avulsed consist essentially of DREZ fibers at T13.31. The rodent model according to claim 26 , wherein aberrant activity is observed in Rexed laminae 1-3.32. The rodent model ...

Подробнее
Номер записи: 99
13-02-2014 дата публикации

ANKYRIN G AND MODULATORS THEREOF FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS

Номер: US20140044644A1
Автор: GRIMM Jan, Hock Christoph, Merlini Mario, Nitsch Roger, Santuccione Chadha Antonella
Принадлежит: University of Zurich

The present invention generally relates to the technical field of medicine, in particular to the field of neurodegenerative, neurological and protein misfolding disorders such as amyloidosis. By establishing a role of ankG in APP processing the method of the present invention provides a new insight into the role of ankG in AD pathology and provides ankG as a target, drug, diagnostic agent and particularly as a vaccine in the treatment and diagnosis of the pathogenesis of Alzheimer's disease (AD). 128.-. (canceled)29. A method of reducing brain amyloid-beta protein (Aβ) pathology by lowering brain levels of Aβ comprising administering to a subject in need thereof a therapeutically effective amount of an agent selected from the group consisting of:a) a recombinant ankG protein or a fragment, derivative or analog thereof;b) an ankG-binding molecule;c) an anti-ankG antibody; and,d) a polynucleotide that reduces the expression or the cortical level of ankG protein in the brain.30. The method of claim 29 , wherein the agent is an ankG-binding molecule that is a fragment claim 29 , derivative or analog of amyloid precursor protein (APP) derived from the intracytoplasmatic domain of APP.31. The method of claim 29 , wherein said agent is formulated for administration as a vaccine.32. The method of claim 31 , wherein the vaccine induces autoantibodies against ankG in the subject.33. The method of claim 29 , wherein the agent is a polynucleotide selected from the group consisting of triple helix DNA claim 29 , an antisense nucleic acid claim 29 , a microRNA claim 29 , double stranded RNA claim 29 , a ribozyme claim 29 , a small interfering RNA (siRNA).34. A method of diagnosing a neurological disorder in a subject comprising detecting in a body fluid obtained from a subject the presence of an anti-ankG autoantibody claim 29 , wherein the presence of claim 29 , or an elevated level of the anti-ankG autoantibody compared to the level present in a control sample from an ...

Подробнее
Номер записи: 100